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Salivary gland cancer (SGC) comprises less than 5% of head and neck 
malignancies. SGCs can occur in both major and minor salivary glands. 
Approximately 60 new cases of major SGC occur annually in Finland. 
Unfortunately, national statistics does not show the annual number of minor 
salivary gland (MiSG) SGCs. The World Health Organization (WHO) classifies 
19 histologically distinct SGCs. The etiology of SGC is unknown and the risk 
factors include smoking, alcohol consumption, increased age, female sex, 
ionizing radiation, and occupational exposure, e.g. to rubber and nickel. In 
addition, oncoviruses might increase the risk for SGC. 
Adenoid cystic carcinoma (ACC) is denoted as the second most common 
SGC worldwide. In Finland, ACC is the most common histological subtype 
according to a nationwide study. ACC is a slow-growing neoplasm and has a 
tendency for perineural invasion. ACC shows three distinct histological growth 
patterns: cribriform, tubular, and solid. Surgery is the pivotal treatment 
modality, but treatment is modified according to tumor site, biological 
aggressiveness, and stage of the disease, which is determined according to the 
Union for International Cancer Control (UICC) Tumor-Node-Metastasis 
(TNM) classification. Postoperative radiotherapy is recommended for all 
patients, but chemotherapy is used mainly for inoperable, recurrent, or 
metastatic disease. Recurrencies affect approximately 50% of patients. 
Especially local and distant recurrent tumors are fairly common, with distant 
metastasis being more frequent and lungs the most common site. ACC has a 
good 5-year disease-specific survival (76-88%), but the 10-year survival (34-
67%) is clearly worse. Prognostic factors affecting survival are tumor site, TNM 
classification, histology, surgical margin status, and distant metastasis. 
In this thesis, the goal was to collect all patient data and tumor samples of 
the MiSG ACC patients diagnosed between years 1974 and 2012 in the Helsinki 
University Hospital area. Patient and tumor characteristics, treatment, 
outcome, and their associations were studied. To evaluate the viral role in ACC 
samples, the presence of three polyomaviruses were assessed by the qPCR 
method and genotyping of 24 human papillomaviruses (HPV) was performed 
with a Multiplex HPV Genotyping Kit. Furthermore, by 
immunohistochemistry matrix metalloproteinase (MMP)-7, -8, -9, -15, and -
25 and antizyme inhibitor (AZIN) 1 and 2 in ACC were studied. 
In this study, the most common tumor site was the palate. Of patients, 94% 
were treated with curative intent. Moreover, 53% of patients suffered from 
recurrent ACC of which 36% were local, 12% regional, and 52% distant. Almost 
all distant metastases appeared within 10 years. The 5- and 10-year overall 
survival and disease-specific survival were 70% and 79%, and 42% and 52%, 
respectively. Stage I ACC patients had better survival than patients with higher 
stages (II-IV). Of interest, John Cunningham polyomavirus (JCPyV) DNA was 
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found in 10% of the tumor samples. In the immunohistochemical studies on 
MMPs, abundant MMP-7 and -25 were associated with better survival. High 
tumorous MMP-9 associated with advanced stage and high MMP-15 
immunoexpression with poorer survival. Intriguingly, abundant MMP-9 
immunoexpression in inflammatory cells in the vicinity of ACC and in luminal 
material of pseudocysts of ACC associated with better survival and fewer local 
recurrent tumors. Immunoexpression of AZIN2 was abundant in well-
differentiated tumor tissue (cribriform and tubular), but in the solid pattern 
the expression was negative or mild. AZIN2 immunoexpression associated 
with better survival. 
To conclude, these results show that especially stage II ACC should be 
considered as advanced disease and patients would benefit from more 
aggressive treatment. Follow-up time should be prolonged for at least ten 
years. JCPyV could participate in the pathogenesis of a small proportion of 
ACC. MMPs could participate in ACC carcinogenesis by tissue modulation, 
activating different signaling pathways, and by immunomodulation. MMP-7, 
-9, -15, and -25 are related to prognostic factors. High AZIN2 
immunoexpression in well-differentiated ACC could be related to a 
functioning vesicle transport system of tumor cells that no longer exists in 
poorly differentiated ACC tissue. AZIN2 could be a prognostic factor for better 
survival of ACC patients. 
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SUMMARY IN FINNISH 
Sylkirauhasten syövät ovat harvinaisia. Pään ja kaulan alueen syövistä ne 
käsittävät alle 5 %. Sylkirauhassyöpiä esiintyy suurissa ja pienissä 
sylkirauhasissa. Suomessa suurten sylkirauhasten syöpiä ilmaantuu 
vuosittain noin 60. Pienten sylkirauhasten syöpien ilmaantuvuutta ei tällä 
tarkkuudella tiedetä, koska näille ei ole omaa vastaavaa luokitusjärjestelmää. 
Maailman terveysjärjestö (WHO) luokittelee histologisesti 19 eri 
sylkirauhassyöpää. Sylkirauhassyöpien etiologia on tuntematon. 
Riskitekijöinä pidetään tupakointia, alkoholin käyttöä, korkeaa ikää, 
naissukupuolta, ionisoivaa säteilyä sekä tietyistä ammateista johtuvaa 
altistumista esimerkiksi kumille tai nikkelille. Myös onkovirukset saattavat 
lisätä sylkirauhassyövän riskiä. 
Adenokystinen karsinooma (ACC) on toiseksi yleisin sylkirauhassyöpä 
maailmassa. Suomessa ACC on yleisin sylkirauhassyöpä. ACC kasvaa 
tyypillisesti hitaasti ja tunnusomaista on perineuraalinen invaasio. 
Histologisesti ACC:ssa esiintyy kolmea erilaista kasvutapaa: kribriforminen, 
tubulaarinen ja solidi. ACC hoidetaan kirurgisesti. Hoito räätälöidään 
potilaskohtaisesti kasvaimen paikan, arvioidun biologisen aggressiivisuuden 
sekä kasvaimen edenneisyysasteen (stage) mukaan, joka määritellään 
kansainvälisen luokittelun perusteella (the Union for International Cancer 
Control (UICC) Tumor-Node-Metastasis (TNM) classification). Kirurgian 
jälkeistä sädehoitoa suositellaan kaikille ACC potilaille. Kemoterapiaa 
tarjotaan potilaille, joiden kasvainta ei pystytä leikkaamaan sekä taudin 
uusiessa tai lähettäessä etäpesäkkeitä. Tautiuusiutumia esiintyy noin 50 %:lla 
potilaista. Tavallisimmin ACC joko uusiutuu alkuperäiselle paikalleen tai 
lähettää etäpesäkkeitä keuhkoihin. ACC:n tautispesifinen viisivuotisennuste 
on korkea (76-88 %), mutta 10-vuotisennuste (34-67 %) on alhaisempi. 
Selviytymistä ennustavat kasvaimen sijainti, histologinen kasvutapa, 
leikkausmarginaalit, levinneisyysluokitus sekä etäpesäkkeiden esiintyminen. 
Väitöskirjatutkimuksessa kerättiin potilastiedot ja kasvainnäytteet pienten 
sylkirauhasten ACC potilailta, jotka oli hoidettu vuosien 1974-2012 aikana 
Helsingin yliopistollisessa keskussairaalassa. Näistä tutkittiin potilas -ja 
kasvainkohtaiset tunnusmerkit, hoitokäytännöt, selviytyminen sekä näiden 
väliset mahdolliset yhteydet. qPCR-menetelmällä kasvainnäytteistä 
määritettiin kolmen polyoomavirustyypin esiintyminen ja lisäksi tehtiin 24:n 
ihmisen papilloomaviruksen tyypitys. Immunohistokemiallisina värjäyksinä 
tehtiin matriksin metalloproteinaasi (MMP) -7, -8, -9, -15 -ja 25 ja antizyme 
estäjät (AZIN) 1 ja 2. 
Pienten sylkirauhasten ACC esiintyi yleisimmin suulaessa. Potilaista 94 % 
hoidettiin kuratiivisesti, joista 53 %:lla ACC uusiutui. 36 %:ia 
tautiuusiutumista oli paikallisia ja 12 %:ia sijaitsi kaulalla. 52 %:lle potilaista 
tuli etäpesäkkeitä, jotka ilmestyivät valtaosin 10 vuoden aikana taudin 
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diagnosoimisesta. Viisi ja kymmenen vuotinen kokonaisselviytyminen ja 
tautikohtainen selviytyminen olivat 70 ja 79 % sekä 42 ja 52 %. Stage I ACC 
potilaat selviytyivät paremmin verrattuna stage II-IV-potilaisiin. John 
Cunningham polyoomavirusta (JCPyV) esiintyi 10 %:ssa ACC-näytteitä. 
Immunohistokemiallisissa tutkimuksissa runsas MMP-7 ja -25 
immunovärjäytyvyys yhdistyivät parempaan selviytymiseen. Runsas MMP-9 
värjääntyvyys yhdistyi taudin levinneisyyteen ja MMP-15 heikompaan 
selviytymiseen. Lisäksi havaittiin tulehdussolujen ja ACC:n luminaalisten 
pseudokysta-alueiden runsaan MMP-9 immunovärjäytymisen yhdistyvän 
sekä parempaan selviytymiseen että vähäisempään määrään paikallisia 
uusiutumia. AZIN2 immunovärjäytyvyys oli puolestaan yleisempää hyvin 
erilaistuneissa kasvaimissa (kribriforminen ja tubulaarinen kasvutapa) 
verrattuna huonosti erilaistuneisiin (solidi kasvutapa) kasvaimiin. Runsas 
AZIN2 immunovärjäytyvyys yhdistyi lisäksi parempaan ennusteeseen. 
Nämä tulokset osoittavat, että erityisesti stage II ACC:tä on pidettävä 
pidemmälle edenneenä kasvaimena ja potilaat voivat hyötyä tehokkaammasta 
hoidosta. ACC:n kliinisen seurannan tulisi olla ainakin 10 vuotta, jotta 
mahdollisimman monet etäpesäkkeet havaittaisiin nopeasti. Tutkimus antoi 
viitteitä, että JCPyV mahdollisesti osallistuu ACC:n kehittymiseen. Myös 
MMP:t voivat osallistua ACC:n syntyyn muokkaamalla kudoksia, aktivoimalla 
signaalireittejä sekä muokkaamalla paikallista puolustusvastetta. MMP-7, -9, 
-15 ja -25 olivat yhteydessä ACC:n ennusteeseen. Runsas AZIN2 värjäytyvyys 
hyvin erilaistuneessa ACC:ssa voi liittyä sen osallisuuteen kasvainsolun 
toimivassa vesikkelien kuljetussysteemissä, joka ei mahdollisesti toimi enää 
huonosti erilaistuneessa kasvaimessa. AZIN2 värjääntyvyyttä voisi siten 





Infrequent salivary gland cancers (SGC) form a heterogeneous group 
comprising 19 histological subtypes 1. SGCs can occur in both major (MaSG) 
and minor (MiSG) salivary glands. MiSGs are small glandular structures 
located in the oral cavity and oropharynx. Similar small excreting glands are 
distributed in the aerodigestive tract and in the ears. In this thesis study, all 
minor salivary, mucous, and ceruminous glands in the head and neck area 
were included into the category of MiSGs. Tumors occurring in MiSGs are 
malignant in 40-90% of cases and most often, epithelial in origin 1. Hence, 
here, these malignancies are called SGCs. 
Adenoid cystic carcinoma (ACC) is the second most common SGC 
worldwide, but in a few nationwide studies, including Finland, ACC is denoted 
as the most common SGC 1-4. ACC is reported as the most common MiSG 
malignancy, frequently seen in the palate 2, 3, 5-7. 
ACC is diagnosed often at 50 years of age and the disease shows a female 
predilection 6, 8. Clinically, ACC is described as an unpredictable high-grade 
neoplasm with a tendency to produce both local and distant metastases even 
after a long follow-up 7, 8. Treatment is surgical with or without radiotherapy, 
and chemotherapy is usually used in advanced, recurrent, or metastatic 
diseases 8, 9. Prognostic factors include the Union for International Cancer 
Control (UICC) Tumor-Node-Metastasis (TNM) classification, tumor location, 
histology, surgical margins, perineural invasion, and recurrencies 8, 10, 11. For 
ACC, 5- and 10-year disease-specific survival (DSS) rates are 76-88% and 34-
67%, respectively 8, 11. 
Etiology of SGC or ACC is not well-known. Risk factors for SGC include 
ionizing radiation 12, industrial exposure to rubber or nickel 13, and previous 
primary cancer 14, 15. A recently described ACC-specific oncogenic event is gene 
translocation of MYB, resulting in a fusion of the myeloblastosis (MYB) 
oncogene to the transcription factor nuclear factor I/B (NFIB) 16. Although the 
fusion gene does not seem to determinate prognosis 17, it could be used as a 
biomarker in diagnostics 18. 
This study aimed to investigate the clinical presentation, treatment, and 
outcome of MiSG ACC patients in the Helsinki University Hospital district. 
Moreover, the aim was to assess the presence of human polyomaviruses 
(HPyV) and human papillomaviruses (HPV) in ACC in order to examine the 
role of viruses in the carcinogenesis of ACC. Matrix metalloproteinases (MMP) 




2. REVIEW OF THE LITERATURE 
2.1 SALIVARY GLANDS 
Salivary glands are divided into MaSGs and MiSGs. MaSGs consist of three 
paired glands, namely the parotid gland, submandibular gland, and sublingual 
gland. Small glandular structures beneath the epithelium in the head and neck 
area are called minor salivary and mucous glands, MiSGs. Recently, Valstar et 
al. have reckoned to discover a new pair of salivary glands, the tubarial salivary 
glands, in the nasopharynx 19. 
 
2.2 ANATOMY AND MORPHOLOGY OF MINOR 
SALIVARY GLANDS 
 
Between 450 and 1000 MiSGs are distributed in the aerodigestive tract 
(oral cavity, oropharynx, nose, paranasal sinuses, pharynx, larynx, and 
trachea) 20. Th bronchi and esophagus have the similar small glands. MiSGs, 
sized 1-5 mm, are unencapsulated and located beneath the surface epithelium. 
MiSGs are responsible for production and secretion of mucous and 
seromucous saliva that aid mastication, deglutition, digestion, and further 
protects teeth and mucosa. 21 
Small glandular structures in the external auditory canal are called 
ceruminous glands; these are located beneath the skin. The number of 
ceruminous glands varies between 1000 and 2000. These modified apocrine 
glands produce cerumen, which protects the ear from physical damage and 
microbial invasion. 22 
The acinar-ductal unit is the basic structure of all salivary and similar 
glands, and it is composed of epithelial and myoepithelial cells (Figures 1 and 
2). Acinus is formed by small, pear-shaped groups that are surrounded by 
basement membrane. Acinus cells are serous or mucous. Serous cells are 
pyramid-shaped with cytoplasm filled with zymogen granules. Their nuclei are 
basally oriented and the cytoplasm stains basophilic. Mucinous cells consist of 
a round, basal nucleus and cytoplasm with vacuoles containing mucin. At the 
periphery of the acini, there are myoepithelial cells capable of contraction. 
Acini form several secretory units that open via short ducts directly through 
the mucosa. 21 The ductal system of MiSG is minimalistic with shorter tracts 
than in the MaSG 23. 
16
Figure 1. Acinar-ductal unit of the salivary gland. Epithelial cells appear
in yellow and myoepithelial cells in pink. Courtesy of Ruusu Hulmi.
Figure 2. Acinar-ductal unit (arrow) of the mucous gland in the sinonasal 
cavity. Magnification x 10. Courtesy of Professor Jaana Hagström.
2.3 EPIDEMIOLOGY OF SALIVARY GLAND CANCER 
(SGC) AND ADENOID CYSTIC CARCINOMA (ACC)
Annual incidence of epithelial malignancies of major and minor salivary 
glands varies from 0.3 to 3 per 100 000 24. SGC represents 0.5% of all 
malignancies and 3% to 5% of all head and neck malignancies worldwide 25, 26. 
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Malignancies of MiSGs account for 10% to 20% of all SGCs 20, 26. 
Approximately 60 new cases of MaSG SGCs are diagnosed in Finland annually. 
According to the Finnish Cancer Registry, the age-adjusted incidence rates per 
100 000 person-years between years in 2015-2019 were 1.5 for females and 
1.33 for males with MaSG SGC (www.cancer.fi). Due to the lack of TNM 
classification exclusively for MiSG malignancies, the incidence rates for MiSG 
SGCs are not available from the Finnish Cancer Registry. 
ACC represents less than 1% of head and neck malignancies and 10% of all 
salivary gland neoplasms. Approximately 30% of minor SGCs are ACC. 27, 28 
ACC is the second most common SGC worldwide after mucoepidermoid 
carcinoma 1, but in nationwide studies from Finland and Denmark ACC has 
been shown to be the most common SGC subtype 2, 3. According to location, 
ACC is the most common entity of SGCs in the sinonasal cavities, larynx, 
trachea 10, and external ear canal 21. ACC of oral cavity and oropharynx is 
reported to be the most common or the second most common SGC subtype 7, 
10. The Finnish Cancer Registry does not directly report the annual number of 
new cases of MiSG SGCs or ACCs. A medical record system search found three 
MiSG ACC diagnoses in 2018 in the Helsinki University Hospital district. 
 
2.4 RISK FACTORS FOR SGC 
 
Risk factors for SGC are largely unknown. Specific risk factors for ACC have 
not been recognized. Smoking, alcohol consumption, gender, and aging are 
cancer risk factors in general and these are also related to SGC 13, 29. 
Based on studies of atomic bomb survivors, ionizing radiation is a well-
known risk factor for SGC 12. Heavy doses of ionizing radiation to the head and 
neck area increase the prevalence of oral and oropharyngeal adenocarcinomas 
rather than squamous cell carcinomas (SCCs) 12. In addition, cervicofacial 
radiotherapy has been shown to be a risk factor for SGC 14. 
According to an epidemiological study, several occupations and industries 
are potential risk factors for SGC 14. Especially workers in rubber or nickel-
using industries have an increased risk for SGC 13. 
Previous primary cancer increases the risk for SGC 14, 15. Falchook et al. 
discovered that any previous cancer elevates the risk for a second primary 
SGC, particularly among women 15. 
Oncoviruses as etiological factors have been studied in SGC with varying 
results. Studies concluding against a viral etiology are more numerous than 
studies supporting oncoviruses as etiological factors. HPVs, such as HPV16 
and 18, human herpes virus 8, and Epstein-Barr virus (EBV) have been shown 
not to participate in the etiopathogenesis of SGC 30-32. However, Hühns et al. 
have provided a weak evidence that HPV infection could be part of the salivary 
gland tumor etiopathogenesis 32. EBV infection has been shown to be 
associated with a rare SGC, namely lymphoepithelial carcinoma, in certain 
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populations of indigenous people. In the Western population, the association 
is infrequent. 1 
 
2.5 MOLECULAR PATHOGENESIS OF ACC 
 
The molecular pathogenesis of ACC is not yet well-recognized. Recently, 
the key oncogenic event of ACC has been described to be the gene translocation 
of MYB t(6;9)(q21-24;p13-23) 16. This translocation results in a fusion of the 
myeloblastosis (MYB) oncogene to the transcription factor nuclear factor I/B 
(NFIB) 16. It affects at least 50% of ACC tumors 33. The activity of MYB-NFIB 
fusion gene leads to elevated levels of MYB transcript and overexpression of 
the protein Myb 33. MYB is frequently overexpressed in ACC with MYB-NFIB 
fusion gene, although the overexpression is detected as well in fusion-negative 
ACC 34. In addition, ACC shows more rarely a t(8;9) translocation in which 
MYBL1 oncogene and transcription factor gene NFIB form a fusion 1. 
MYB/MYBL1 fusions have not been found in other salivary gland tumors and 
can be used as a biomarker for facilitating diagnostics 34-37. According to a 
recent meta-analysis, (t6;9) (MYB-NFIB) does not determine prognosis 17. 
The Notch pathway alterations have been identified in ACC 1, 38, 39. Chen et 
al. have shown that NOTCH1 knock-down decreases the growth and migration 
of ACC cells in vitro and metastatic potential in vivo 40. NOTCH1 alterations 
are associated with the behavior of ACC, and this mutation type defines a 
subgroup of ACCs with more solid histology, liver and bone metastases, and 
otherwise poor prognosis 41. 
A transmembrane tyrosine kinase receptor c-kit protein (cluster of 
differentiation 117 [CD117]) is a growth factor expressed by the luminal 
epithelial cells of ACC. c-kit expression has been detected in 90% of ACC 
tumors, which have been shown to be associated with high-grade tumors. 42 
Myoepithelial cells of ACC express extensively an epidermal growth factor 
receptor (EGFR). High expression levels of EGFR are associated with 
advanced histological grade 43. The mechanisms of c-kit and EGFR in the 
pathogenesis of ACC is not fully understood. They are frequently 
overexpressed in ACC but infrequently mutated or amplified 1. 
2.6 DIAGNOSIS OF ACC 
2.6.1 SYMPTOMS 
 
Presenting symptoms in MiSG and MaSG SGCs are largely similar. 
According to the review article by Coca-Pelaz et al. the most common 
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symptoms are slowly growing mass and pain 7. Symptoms may vary due to site 
and tumor size. ACC occurring in the palate might present a mass resembling 
a fibroma, ulceration, or even an oro-antral fistula to the maxillary sinus 7. 
Initial symptoms in ACC of paranasal sinuses are described to be pain, 
unilaterally blocked nose, and repeated epistaxis 44. Studies concerning MiSGs 
of the oral cavity, oropharynx, and upper respiratory tract list symptoms such 
as lump, pain, ill-fitting denture, salivary duct blockage, ulceration, and 
delayed healing 45, 46. Detection of regional metastasis or metastatic disease at 
the time of initial diagnosis is uncommon. Shum et al. reported 3.6% cervical 
and 7.1% distant metastasis at the diagnosis of MiSG ACC 46. 
2.6.2 HISTOLOGICAL DIAGNOSIS 
 
At the cellular level, ACC tissue consists of epithelial and myoepithelial 
cells. The tumor cells are small, cuboidal, and basophilic with hyperchromatic 
nuclei and scant cytoplasm 1, 21. 
WHO classification (2017) divides SGCs into 19 different histological 
subtypes (Table 1). ACC is graded as the second most common histological 
subtype. 1 Histologically, ACC tissue presents different growth patterns, 
namely cribriform, tubular, and solid (Figures 3 and 4). 1, 47 A single tumor can 
present various growth patterns, but the richest pattern determines the 
classification. Cribriform and tubular growth patterns are more frequent than 
solid. A tumor that consists of more than one-third of solid type shows 
aggressive behavior. 47 
 
Table 1. World Health Organization (WHO) classification of malignant 
salivary gland tumors according to WHO/IARC, 4th edition 1. 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Polymorphous adenocarcinoma 
Clear cell carcinoma 
Basal cell adenocarcinoma 
Intraductal carcinoma 
Adenocarcinoma, not otherwise specified 
Salivary duct carcinoma 
Myoepithelial carcinoma 
Epithelial-myoepithelial carcinoma 




Poorly differentiated carcinoma 
Undifferentiated carcinoma 
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Large cell neuroendocrine carcinoma






Figure 3. Growth patterns of adenoid cystic carcinoma. A: Cribriform. B: 




Figure 4. Emulation of a ducto-acinar unit of salivary gland (above) in 
different growth patterns of adenoid cystic carcinoma. Epithelial cells appear 
in yellow and myoepithelial cells in pink. A: In the cribriform growth pattern, 
epithelial cells form ductal structures surrounded by myoepithelial cells and 
pseudocysts containing glycosaminoglycans and basal lamina. B: Tubular 
structures are formed when inner epithelial cells are surrounded by a single to 
a few layers of myoepithelial cells. C: The solid growth pattern is formed with 
the proliferation of neoplastic myoepithelial cells along with a few ductal 
structures. 47 Courtesy of Ruusu Hulmi. 
 
From a representative biopsy sample, a pathologist is able to diagnose the 
subclassification of the SGC and evaluate the histological grade. From a 
histological perspective, several SGCs share similar features. To determine the 
correct diagnosis, it is important to see the tumor surroundings and to perform 
immunohistochemical staining. Immunohistochemical markers that aid in 
differentiating between epithelial and myoepithelial cells have been used in 
ACC diagnostics. These are CD117, p63, and smooth muscle actin (SMA) 1. 
CD117 shows the presence of inner epithelial tumor cells, and p63 and SMA 
stain peripheral myoepithelial tumor cells 1, 48, 49. Epithelial membrane antigen 
(EMA) and carcinoembryonic antigen (CEA) do not stain pseudocysts of ACC 
but are positive in the true glands of ACC 50. New tools for challenges in 
diagnostics are MYB immunohistochemistry and MYB break-apart 
fluorescent in situ hybridization (FISH) 36. 
In case of ACC, differential diagnoses to exclude are pleomorphic adenoma, 
polymorphous adenocarcinoma (PAC), secretory carcinoma (SC), epithelial-
myoepithelial carcinoma (EMC) and basal cell adenocarcinoma (BAC). PAC 
tissue is immunohistochemically positive for cytokeratin-7 (CK7), S-100 
protein, CEA, mammaglobin, and basal and myoepithelial cell marker p63. In 
addition, ACC usually has a higher Ki-67 proliferation index. SC originates 
from one cell type. SC immunoexpress mammaglobin, vimentin, and S-100. 
EMC has a biphasic nature, as does ACC; the inner luminal epithelial cells 
express CK7 and the outer myoepithelial cells p63, SMA, and calponin. 
Collagen type IV staining is positive in the surrounding stroma of basement 
membrane material. Ki-67 shows variable expression. BAC shows dual-cell 
composition, whereas CK7 stains epithelial cells and SMA immunoexpression 
is seen in myoepithelial cells. Compared with basal cell adenoma, BAC shows 
invasion. Compared with ACC, BAC shows more vesicular nuclei, peripheral 
palisading, and more squamous and sebaceous parts. 1, 37 
2.6.3 PREOPERATIVE INVESTIGATIONS 
 
Preoperative imaging options for patients with suspected or confirmed 
MiSG malignancy are computed tomography (CT) and magnetic resonance 
imaging (MRI). CT and MRI show the exact location and size of the tumor in 
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relation to major neurovascular structures, perineural and skull base invasion, 
and intracranial extension 51. CT is used to delineate bone invasion. MRI 
reveals better soft tissue extensions such as neural or soft tissue invasion, 
diffuse growth patterns, and lymphadenopathy 7. Imaging should also provide 
accurate staging of the regional lymph nodes and evaluation of distant 
metastases 51. In addition, fine-needle aspiration could be used for assessing 
the diagnosis although this technique is not widely used for MiSG tumors. 
2.6.4 STAGING 
 
The stage of the disease depending on tumor size, lymph node involvement, 
and distant metastasis is determined according to UICC TNM classification 52. 
Currently, TNM classification is exclusively used for malignancies of MaSGs. 
Due to the lack of a specific staging system, the classification of MiSG 
malignancies is performed according to the corresponding classification of the 
head and neck SCC in the same location. Table 2 shows TNM classification of 
malignant tumors in the lip and oral cavity. 
 
Table 2. Tumor-Node-Metastasis (TNM) classification of malignant 
tumors in the lip and oral cavity according to the Union for International 
Cancer Control, 8th edition 52. 
T-Primary tumor  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor 2 cm or less in greatest dimension 
and 5 mm or less in depth of invasion 
T2 Tumor 2 cm or less in greatest dimension 
and more than 5 mm but no more than 
10mm in depth of invasion or tumor 
more than 2cm but not more than 4cm in 
greatest dimension and depth of 
invasion no more than 10mm 
T3 Tumor more than 4 cm in greatest 
dimension or more than 10mm in depth 
of invasion 
T4a (Lip) Tumor invades through cortical 
bone, inferior alveolar nerve, floor of 
mouth, or skin (of the chin or the nose) 
T4a  (Oral cavity) Tumor invades through the 
cortical bone of the mandible or 




T4b (Lip and oral cavity) Tumor invades 
masticator space, pterygoid plates, or 





NX Regional lymph nodes cannot be 
assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph 
node, 3 cm or less in greatest dimension 
without extranodal extension 
N2 Metastasis described as: 
 N2a: Metastasis in a single ipsilateral 
lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension, 
without extranodal extension 
N2b: Metastasis in multiple ipsilateral 
lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal 
extension 
N2c: Metastasis in bilateral or 
contralateral lymph nodes, none more 
than 6 cm in greatest dimension, without 
extranodal extension 
N3a Metastasis in a lymph node more than 6 
cm in greatest dimension without 
extranodal extension 
N3b Metastasis in a single or multiple lymph 
nodes with clinical extranodal extension 
M-Distant metastasis  
M0 No distant metastasis 




The principal treatment for all SGCs is surgery with or without 
radiotherapy (RT) 9, 20, 26, 51, 53, 54. For MiSG cancer, the treatment strategy is 
customized depending on the site, extent of disease, histological grade, and 
biological behavior 20. 
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2.7.1 TREATMENT OF THE PRIMARY SITE 
 
The goal of the surgical approach is to ensure adequate tumor-free margins. 
However, the concept of adequate free margins is not well-established in 
MiSGs. Especially MiSG ACC often infiltrates into adjacent tissues and 
achieving free margins might be challenging. Intraoperative pathologic 
examination, i.e. frozen section, supports the surgeon since a frozen section 
study is shown to be a reliable aid in intraoperative decision-making. 9 The 
surgical approach varies from open to endoscopic depending on the location. 
In the oral cavity, for a localized low-grade tumor a wide excision might be the 
only treatment modality. For advanced tumors radical surgery 
(mandibulectomy or maxillectomy) with postoperative RT is the treatment of 
choice. 20, 51 Laryngeal ACC is often diagnosed as advanced and non-operable. 
Definite RT is a treatment alternative for a total laryngectomy 55. 
2.7.2 TREATMENT OF THE NECK 
 
Surgical treatment of the neck is planned individually based on the disease 
and most often neck dissection is selective. Among minor SGC patients, 15% 
have a clinical or radiologic sign of neck metastasis (N+) 20. In ACC, Amit et 
al. have observed 16% of patients to have N+ neck at presentation, and the 
total proportion of histologically confirmed neck metastasis was as high as 
29% 56. In the primary treatment of ACC, RT is seldom used as a sole treatment 
modality for the neck. Surgical treatment of the neck combined with RT has a 
significantly better survival outcome than RT alone 57. 
Treatment of patients without clinically evident neck metastasis (N0) is 
controversial. Recent guidelines recommend offering elective neck dissection 
(END) to SGC patients with T3 and T4 tumors and high-grade malignancies 9. 
END is not routinely performed in ACC. Xiao et al. have shown an association 
between END and longer overall survival (OS) of patients with advanced ACC 
58. Occult neck metastases have been shown in 15-44% of ACC patients 56, 59 
which might support END decision. In addition, ACC in the oral cavity and 




A recent guideline recommends postoperative RT to all patients with ACC 
9. Postoperative RT is an effective method to prevent local recurrent tumors 
among MiSG ACC patients 60, 61. RT is suggested for high-grade and advanced 
tumors, positive margins, perineural, vascular, lymphatic, or bone invasion, 
lymph node metastasis, recurrent tumors, and such locations such as 
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sinonasal cavities, oropharynx, and floor of mouth 9, 51. The optimal treatment 
approach is a dose of 60 Gy in 30 fractions for most MiSG cancer patients 60. 
Primary RT is used for patients with medically or technically inoperable 
tumors and for palliative treatment 62, 63. Definite proton beam therapy could 
be used as an alternative treatment modality since it is shown to give 
promising local control for patients with inoperable ACC 64. 
2.7.4 CHEMOTHERAPY 
 
The role of chemotherapy in ACC is generally restricted to inoperable or 
recurrent tumors and metastasis 65, 66. Even though the response rate to 
chemotherapy is low, this treatment can relieve symptoms of ACC patients 67. 
The studies on chemotherapy agents usually have small numbers of 
participants, and the response rates to chemotherapy agents have been modest 
65, 66. For salivary gland ACC, the first-line chemotherapy options are 
mitoxantrone, vinorelbine, or epirubicin, but neither paclitaxel nor cisplatin is 
recommended. For combination chemotherapy, the available studies suggest 
cisplatin and anthracycline, although the combination has more toxic effects 
than single-agent chemotherapy. 66 
 
2.8 PROGNOSIS AND PROGNOSTIC FACTORS 
The prognosis of ACC is generally considered disheartening due to the poor 
long-term survival rates. Five-year survival is usually high, whereas the 10-
year survival curve drops markedly. For MiSG ACC, depending on the study, 
5- and 10-year OS rates are 62-92% and 54-72%, respectively 44, 45, 68, 69. The 
corresponding 5- and 10-year DSS rates are 43-76% and 53-74%, respectively 
44, 70, 71. 
Studies on MiSG ACC have shown that independent prognostic factors for 
OS, DSS, and disease-free survival (DFS) are T class 45, 68, 70, N class 68, 70, stage 
44, 68, margin status 68, 70, 72, and solid growth pattern 44. 
Overall, prognostic factors for both MiSG and MaSG ACC are similar. High 
T and N classes, advanced stage, tumor-positive surgical margins, perineural 
invasion, solid growth pattern, aging, and gender are independently related to 
worse survival 44, 45, 68, 70, 72-77. Li et al. showed that MiSG ACC patients with 
neck metastasis at presentation had increased a risk of death compared with 
MaSG ACC patients 78. To gain optimal local control for ACC, radical surgical 
resection with tumor-free margins is crucial 79. According to Bianchi et al., 
positive surgical margins and T3-4 tumors were associated with worse 
locoregional control 70. Sufficient postoperative RT was an independent 
prognostic factor for better OS and local control, whereas chemotherapy did 
not improve prognosis 73, 74. Luksic et al. showed that perineural invasion 
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decreases DSS 71. Solid ACC has been shown to associate significantly with 
lower OS 44, 72. In the solid pattern, tumor cells are highly proliferative, which
partly explains the aggressive behavior. High Ki-67 immunoexpression has 
been revealed to be associated with worse survival of SGC patients 80. In ACC, 
high Ki-67 immunoexpression is shown to be associated with poorer OS, large 
tumor size, and recurrencies 81, 82.
ACC has a propensity for distant metastasis after a prolonged period, which
is related to declining long-term survival. According to previous studies, 31-
38% of ACC patients developed distant metastasis 79, 83. The vast majority of 
distant metastasis occur in the lungs, followed by bone, liver, and brain 79, 83. 
Patients with lung metastasis have a longer survival time than patients with
other distant metastasis sites 83, 84. Distant metastasis rates are high among
MiSG ACCs of the maxillary sinus and tongue 83. In addition, solid growth 
pattern 83 and positive margins 74 predict the occurrence of distant metastasis.
2.9 HUMAN POLYOMAVIRUSES (HPYV)
Thus far, the human polyomavirus (HPyV) family comprises 13 members 
85. These are non-enveloped DNA viruses with circular double-stranded 
genome of size varying from 5100 to 5400 base pairs (bp) (Figure 5) 86.
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Figure 5. Genome of the John Cunningham polyomavirus, 5100 bp. The 
genome consists of a noncoding control region (NCCR) and two 
transcriptional units, namely the early and late regions. Large T antigen and 
small t antigen are encoded by the early gene region, whereas the late region 
encodes viral capsid proteins VP1, VP2, and VP3. 86 Courtesy of Ruusu Hulmi. 
 
BK polyomavirus (BKPyV) and John Cunningham polyomavirus (JCPyV) 
were the first HPyVs identified in the 1970s 87, 88. They can cause serious harm 
to immunocompromised patients. BKPyV infection could lead to 
polyomavirus-associated nephropathy in renal transplant patients. JCPyV has 
a causative role in a fatal central nervous system demyelinating disease, 
progressive multifocal leukoencephalopathy. In the adult population, the 
seroprevalence of BKPyV and JCPyV are 82-99% and 39-81%, respectively 89. 
However, the primary exposure to these viruses is likely to occur in childhood, 
as the seroprevalence in children under 21 years of age is similar to that of the 
adult population 90. 
Simian vacuolating virus 40 (SV40) is not a HPyV but a monkey polyomavirus 
that was inoculated in humans via the SV40-contaminated polio vaccine in the 
1950s until the mid-1960s. Although this mode of SV40 transmission is no 
longer possible, the estimated SV40 seroprevalence is 2%, in both adults and 
children 90. SV40 is capable of causing cancer in animal models 91. 
2.9.1 HPYVS IN CANCER 
 
According to an estimation by de Martel et al., in 2018 oncogenic viruses 
globally caused 8.3% of human cancers 92. The International Agency for 
Research on Cancer (IARC) has classified seven viruses (EBV, hepatitis B 
virus, hepatitis C virus, Kaposi´s sarcoma herpes virus or human herpes virus 
8, human immunodeficiency virus type-1, human T-cell lymphotropic virus 
type 1, and HPV) as group 1 human carcinogens (carcinogenic to humans). It 
is noteworthy that, IARC has categorized JCPyV and BKPyV as grade 2B 
carcinogens (possibly carcinogenic to humans) and Merkel cell polyomavirus 
(MCPyV) as a group 2A carcinogen (probably carcinogenic to humans) due to 
its association with the development of Merkel cell carcinoma (MCC). Large 
T-ag of HPyV has properties of an oncoprotein because it can interfere with 
tumor suppressor proteins p53 and pRb 93. This oncogenic transformation is 
mediated by T-ag when its expression is uncoupled from the later steps of the 
viral life cycle: viral DNA (deoxyribonucleic acid) replication, late gene 
expression, virion assembly, and host cell lysis. Consequently, T-ag inactivates 
signal transduction pathways and tumor suppressor proteins pRb and p53 
leading to neoplastic formation. 89, 94 
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2.9.2 HPYVS IN HEAD AND NECK CANCER 
 
Previous studies concerning head and neck SCC have detected BKPyV in 
oropharyngeal SCC 95 and JCPyV in tongue, pharyngeal, and laryngeal SCC 96, 
97. Especially in oropharyngeal SCC, Carpén et al. have recently detected 
BKPyV in 30%, JCPyV in 14%, and SV40 in 0.6% of the tumor samples 98. In 
addition, BKPyV, JCPyV, MCPyV, human polyomavirus 6 (HPyV6), human 
polyomavirus 7 (HPyV7), and trichodysplasia spinulosa polyomavirus 
(TSPyV) might stay latent in tonsillar tissue 99-102. However, evidence is still 
lacking for the role of HPyVs in tonsillar tumorigenesis and whether they act 
alone or as a cofactors with HPV 103. 
MCC is a neuroendocrine cutaneous neoplasm that occurs often in elderly 
individuals in the head and neck area. MCPyV is detected in 80% of MCC and 
is confirmed as its etiological factor 104, 105. Whether MCPyV-positive or -
negative MCC has an effect on prognosis remains unclear. However, a few 
studies have shown that patients with MCPyV DNA-positive MCC have a better 
prognosis 105-107. 
The causative role of HPyVs in salivary gland tumors is unclear due to the 
small number of studies on the topic. Chen et al. studied the presence of HPyVs 
in 79 benign and five malignant salivary gland tumors 108. In their study, 
MCPyV was the most frequently detected, followed by BKPyV, JCPyV, SV40, 
human washington university polyoma virus (WUV), HPyV6, and HPyV7. 
Only MCPyV and HPyV6 were detected in malignant tumors (60%). From 
pleomorphic adenoma and warthin´s tumor tissue, HPyVs were detected in 
27% and 50%, respectively. 108 
In 1953, SV40 was shown to promote SGC formation when inoculated into 
new born mice 109. At the time, this new virus was soon verified to have 
tumorigenic properties 110. In addition, Dawe et al. have shown in the 1980s 
that polyomavirus injection could start a formation of salivary gland tumor 
resembling plemorphic adenoma 111. A few studies have shown the varying 
presence of SV40 (2-62%) in pleomorphic adenoma 108, 112. Nowadays, SV40 
does not seem to be prevalent in normal tissues or in malignancies. In the 
modern era, the great importance of SV40 to humans is probably the ability to 
use it in transgenic cancer models 91. 
 
2.10 HUMAN PAPILLOMAVIRUSES (HPV) 
HPVs are small, nonenveloped double-stranded DNA viruses (Figure 6). 
Currently, over 200 HPV genotypes have been identified. HPVs belonging to 
alpha genera infect mucosal epithelia. These HPVs can further be categorized 
as low- (LR) or high-risk (HR) HPV genotypes based on their associated risk 
of malignancy. The following HPV genotypes are included in the list of HR-
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HPVs: HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68, -73, and 
-82. 113
Figure 6. Structure of human papillomavirus 16 genome, 7905 bp. The 
genome consist of three major regions: upstream the long control region 
(LCR), the early (E) gene region, and the late (L) gene region. 113 Courtesy of 
Ruusu Hulmi.
2.10.1 HPVS IN CANCER
In 2018, 834 860 new head and neck SCC cases were registered worldwide 
(GLOBOCAN Registry on Cancers, www-dep.iarc.fr). According to a large 
meta-analysis, 31.5% of head and neck SCCs are HPV positive 114. However, the 
prevalence of HPV-attributable head and neck SCCs varies globally and 
according to anatomic site. In addition, smoking, alcohol consumption, and 
gender have an impact on differences between HPV-positive and HPV-
negative SCCs. 114 To present comparative figures, HR-HPVs are the main risk 
for cervical carcinoma of uteri, causing 80% of these carcinomas 92.
In the carcinogenesis of HPV-attributable cancers, E6 and E7 are the main 
oncoproteins. In brief, by disrupting cellular tumor suppressor pathways p53 
and pRb, E6 and E7, respectively, alter the fundamental cellular events such 
as cell cycle, apoptosis, differentiation, senescence, cell polarity, and activation 
of immune response-related pathways. 115
Studies have shown that HR-HPVs do not have a role in SGCs such as acinic 
cell carcinoma, ACC, mucoepidermoid carcinoma, epithelial-myoepithelial 
carcinoma, myoepithelial carcinoma, basal cell adenocarcinoma oncocytic 
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carcinoma, secretory carcinoma, or salivary duct carcinoma 30, 31, 116. 
Interestingly, recently HR-HPV33 has been found to be related to 
multiphenotypic sinonasal carcinoma, a non-keratinizing SCC that is 
described to have features of both SCC and ACC 117. 
 
2.11 MATRIX METALLOPROTEINASES (MMP) 
MMPs form a zinc-dependent endopeptidase group that has 28 structurally 
related but genetically distinct members, namely collagenases, gelatinases, 
stromelysins, matrilysins, membrane-type (MT) MMPs, and other MMPs 118, 
119. Activated cells express MMPs 118 which process extracellular matrix (ECM) 
mainly composed of collagens 120. In addition, MMPs process non-matrix 
bioactive molecules such as cytokines, hormones, defensins, immune 
mediators, other proteases, adhesion molecules, growth factors, and cell 
surface receptors 119. Thus, in normal conditions, MMPs participate in 
physiological processes such as tissue development and remodeling and 
wound healing 121. Furthermore, MMPs act in tissue destructive diseases 
involving ECM disruption, e.g. vascular disease, bone disorders, 
neurodegenerative disease, and invasion and metastasis of cancer tissue 120. 
2.11.1 MMP-7 OR MATRILYSIN-1 
 
MMP-7 is the smallest MMP and it is expressed by exocrine and mucosal 
epithelial cells, e.g. in salivary glands, skin, breast, intestine, pancreas, and 
liver. Moreover, fibroblasts and neoplastic cells of epithelial origin are able to 
express MMP-7. 118, 122, 123. Interestingly, MMP-7 expression could be induced 
by bacteria via certain structures such as lipopolysaccharide and flagellin 118, 
124. Cytokines and hypoxia can upregulate MMP-7. ECM components, such as 
fibronectin, gelatin, collagen type IV, laminin, and elastin, are among the 
substrates of MMP-7. Cleavage of these substrates leads to breakdown of the 
ECM that is important for regulation of cell migration and tissue remodeling. 
118 MMP-7 could activate MMP-2, -8, and -9 by cleaving their pro-forms 125. 
2.11.2 MMP-8 OR NEUTROPHIL COLLAGENASE OR 
COLLAGENASE-2 
 
MMP-8 was first cloned from neutrophils that were obtained from a patient 
with granulocytic leukemia. However, other cell types (epithelial cells, 
fibroblasts, endothelial cells, monocytes, macrophages, and plasma cells) 
could be induced to express MMP-8. 119 Stromelysin-1 (MMP-3) and MMP-7 
can activate MMP-8 by proteolytic removal of the pro-peptide. The activity of 
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MMP-8 is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1) and 
TIMP-2. 126 MMP-8 functions in normal physiological conditions, such as 
embryogenesis, and in inflammatory condition with massive tissue 
destruction potential, such as periodontitis 119, 126. Moreover, MMP-8 can 
prevent inflammation and cancer formation 127, 128. 
2.11.3 MMP-9 OR GELATINASE B 
 
MMP-9 was first described in neutrophils and the activation is mediated by 
removal of the pro-domain by serine proteases or other MMPs, and due to 
oxidative stress that disrupts the cysteine switch 126, 129. MMP-9 is incapable of 
direct proteolysis of collagen I, but it has the ability to degrade type IV collagen 
of basement membranes 126, 130. Immune and inflammatory cells, such as 
neutrophils, lymphocytes, and dendritic cells, need MMP-9 for migration. 
Lemjabbar et al. have demonstrated that MMP-9 knock-out mice cannot 
recruit these immune cells normally after antigen presentation. 131 Both 
gelatinases MMP-2 and MMP-9 have been shown to participate in pulmonary 
diseases such as asthma and chronic obstructive pulmonary disease 126. Itoh et 
al. first observed decreased tumor angiogenesis and progression in MMP-2 
knock-out mice 132. This observation has led to a wide interest in elucidating 
the role of MMP-2 and MMP-9 in tumorigenesis 132. Currently, MMP-9, 
especially when activated, is agreed to be an important enzyme for tumor 
invasion and metastasis 129, 130, 133. 
2.11.4 MMP-15 OR MT2-MMP 
 
Six MT-MMPs (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, and 
MMP-25) comprise a small and distinct group among MMPs. They differ from 
soluble variants by their quality of remaining anchored to the cell membrane. 
MMP-15 is a ubiquitous enzyme which can activate MMP-2 pro-enzyme 126. 
Physiological functions and the involvement of MMP-15 in pathology are not 
well described. In cancer cell line study of Abraham et al., MMP-15 was shown 
to have anti-apoptotic properties 134. 
2.11.5 MMP-25 OR MT6-MMP 
 
MMP-25 is a neutrophil-specific protease that was first detected in 
leukocytes 135. MMP-25 has important functions in innate immunity due to 
regulating of the chemotaxis of neutrophils and monocytes 136. Various cells 
can shed MMP-25 in exosomes, leading to paracrine transfer to other cells 126. 
MMP-25 can degrade ECM proteins, including fibronectin, type IV collagen, 
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and proteoglycans 126. A wide range of different cancers express MMP-25, 
although studies have not revealed yet the clinical relevance of the expression 
126. 
2.11.6 MMPS IN HEAD AND NECK CANCER 
 
Table 3 shows immunohistochemical studies on MMPs and their 
associations with clinical factors in head and neck SCC. Studies on MMPs in 
SGC are infrequent. In acinic cell and mucoepidermoid carcinomas, MMP-7 
immunoexpression and in epithelial-myoepithelial carcinomas MMP-9 
immunoexpression have been related to better prognosis 122, 137. On the 
contrary, abundant MMP-9 immunoexpression in ACC, mucoepidermoid 
carcinoma, acinic cell carcinoma, and salivary duct carcinoma has been related 
to poorer prognosis 138-141. MMP-9 immunoexpression has been shown to be 
higher in ACC than in normal salivary gland tissue 140, 142. 
 
 
Table 3. Immunohistochemical studies on matrix metalloproteinases and 
their clinical associations in oral and laryngeal squamous cell carcinomas. 
 Tumor 
aggressiveness* 









Oral SCC MMP-7 123, 143, 144 MMP-1, -2, -
3, -7, -9, -14 
145 
MMP-7 123 
MMP-8 and -9 
144 
MMP-8 146 
MMP-9 147 MMP-25 123 
Laryngeal 
SCC 
 MMP-15 148 
MMP-2, -7, -
9 149 
 MMP-9 147 MMP-15 150 
Abbreviations: SCC: Squamous cell carcinoma. MMP: Matrix 
metalloproteinase. * Tumor aggressiveness includes higher tumor grade and 
invasion depth. 
2.12 ANTIZYME INHIBITORS (AZIN) 
Enzymes called antizymes (AZ) and AZINs regulate ornithine 
decarboxylase (ODC), which is the rate-limiting enzyme of the biosynthesis of 
organic cations called polyamines 151, 152. AZs down-regulate post-
translationally ODC, whereas its upregulation is mediated by AZINs 153. A 
mammalian cell uses polyamines for growth, proliferation, differentiation, 
and apoptosis. Consequently, their dysregulation is related to cancer, and 
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polyamine homeostasis has become an interesting target for cancer therapy 151, 
153. AZINs have not been previously studied in head and neck cancer or in SGC. 
New molecular therapies are warranted for SGC among ACC and functions of 
AZINs in ACC would be interesting to clarify. 
2.12.1 AZIN1 AND AZIN2 
 
AZIN1 was first described in 1980s 154. AZIN1 has a stronger affinity to bind 
all three isoforms of AZs than ODC, leading to displacement of ODC from 
ODC-AZ heteromer and to reactivation of ODC 155. Similarly, with ODC, AZIN1 
is ubiquitous in all tissue types, and it is located in the nucleus and cytoplasm. 
AZIN2 was first described at the beginning of the 2000s 156. High amounts 
of AZIN2 are expressed in terminally differentiated cells such as neurons, mast 
cells, megakaryocytes in normal bone marrow, type-2 pneumocytes, 
adipocytes, and acinar cells of sweat glands 157. AZIN2 is predominately 
expressed in the brain and testis, and it localizes in the endoplasmic reticulum-
golgi intermediate compartment 156. In the cell, AZIN2 regulates intracellular 
vesicle transport and the degranulation process of mast cells 152, 158. 
2.12.2 AZINS IN CANCER 
 
Dysregulation in polyamine homeostasis has been related to cancer 
progression 151, 153. Overexpression of ODC enhances carcinogenesis, 
maintaining an invasive and angiogenic phenotype for a tumor cell 159. Thus 
clearly, AZINs might contribute to carcinogenesis. AZIN1 elevates the activity 
of ODC, raising the number of intracellular polyamines that could trigger 
development of gastric, breast, hepatocellular and esophageal cancer 160. In 
particular, disturbance in ribonucleic acid (RNA) editing of AZIN1 has been 
shown to participate in carcinogenesis in hepatocellular carcinoma 161. AZIN2 
is related to the poorer prognosis of colorectal cancer patients although 
specific molecular events are yet to be discovered 162. 
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3. AIMS OF THE STUDY 
The study aimed to assess the factors determining the long-term outcome 
of minor salivary and mucous gland ACC patients. The presence of three 
polyomaviruses and 24 human papillomaviruses was assessed in the ACC 
tissue samples in order to study viral participation in ACC carcinogenesis. 
Knowing that finding new prognostic markers for ACC is warranted, the 
intention was to study the role of MMP-7, -8, -9, -15, and -25, and AZIN1 and 
-2 in minor salivary and mucous gland ACC. 
 
Specific aims of the thesis study were as follows: 
 
1. To evaluate the clinical and histological characteristics of minor 
salivary and mucous gland ACC during a 38-year period at the Helsinki 
University Hospital area in order to clarify their impact on patient 
survival (Study I). 
 
2. To assess the presence of three polyomaviruses (JCPyV, BKPyV, and 
SV40) and 24 human papillomaviruses in minor salivary and mucous 
gland ACC (Study II). 
 
3. To examine distinct biomarkers (MMP-7, -8, -9, -15, and -25) in the 
biology of ACC by immunohistochemistry and to relate the 
immunohistochemical results to clinical characteristics and outcome. 
In addition, to study associations of virus DNA-positive ACCs and 
MMPs (Study III). 
 
4. To examine distinct biomarkers (AZIN1 and -2) in the biology of ACC 
by immunohistochemistry and to relate the immunohistochemical 




4. MATERIALS AND METHODS 
All patients were diagnosed and treated at Helsinki University Hospital. 
Approximately 1.7 million people live in the referral area of Helsinki University 
Hospital. 
 
4.1 STUDY I 
A hospital record search found 86 MiSG ACC patients between 1974 and 
2012. Sixty-eight patients were selected after ensuring adequate patient 
records and confirming and updating histological diagnoses according to the 
WHO classification (2005) by a head and neck pathologist (J.H.). Patient and 
tumor characteristics, treatment, and outcome were described. Tumor staging 
was performed according to the UICC TNM classification 52. Statistics Finland 
provided causes and dates of death. All patients had a minimum follow-up 
time of three years or until death. OS, DSS, and DFS were defined from the 
last day of treatment to the last day of follow up or death (OS), to death due to 
disease (DSS), or to any sign of recurrent tumor (DFS). 
 
4.2 STUDY II 
Sixty-eight tumor samples from 53 MiSG ACC patients were available. The 
samples consisted of 48 primary tumors and in addition 20 recurrent tumors 
from 15 patients. Ten samples of normal salivary gland tissue from the same 
patients were used as controls. Tumor samples were studied to evaluate the 
presence of three polyomaviruses (JCPyV, BKPyV, and SV40) and 24 HPVs. 
Polyomaviruses were detected with quantitative polymerase chain reaction 
(qPCR) and positive samples were further studied for the presence of viral 
tumor T-ag by immunohistochemistry. Tumor samples were analyzed by 
Multiplex HPV Genotyping Kit for the presence of 24 mucosal alpha-HPV 
genotypes. 
4.2.1 DNA EXTRACTION 
 
Formalin-fixed and paraffin-embedded biopsy samples were cut into 5-
μm-thick deparaffinized sections (1 cm2 in total area) and DNA was extracted 
with the high salt method 163. The sections were lysed in lysis buffer (10 mM 
Tris-HCl, 400 mM NaCl, and 2 mM EDTA, pH 8.2) with proteinase K (200 
 
36 
μg/ml) overnight at 37°C. Afterwards, proteins were precipitated with 
saturated NaCl and the DNA with ethanol. 
4.2.2 QUANTITATIVE DETECTION OF JCPYV, BKPYV, AND SV40 
 
Presence of JCPyV, BKPyV, and SV40 DNA in the samples was detected by 
qPCR (Roche, Light Cycler 96, Mannheim, Germany) targeting their 
oncogenic large T-ag. This method has been described earlier by McNees and 
coworkers and was performed here with a slight modification 164. To ascertain 
a relative expression of the target genes, RNase P was used as a reference gene 
(TaqMan® Copy Number Reference Assay RNase, Applied Biosystems, Foster 
City, CA, USA). 
The primers and probes were designed as described earlier 164 and 
produced by Life Technologies as outlined in Table 4. The probes for the target 
genes JCPyV, BKPyV, and SV40 were labeled with 6-carboxyfluorescein 
(FAM). VIC was used for labeling the probe for the reference gene RNase P. 
The qPCR reactions were performed in a 20 μl volume on a micro titer plate 
with conditions as follows: 900 nM of each primer and 100 nM of their 
analogous probe, 10 μl of TaqMan® Universal Mix II, and 300 ng template 
DNA. The manufacturer’s recommendations were used to detect the reference 
gene TaqMan® RNase P (Applied Biosystems). The conditions for all qPCR 
reactions were the following: 2 min at 50°C, 10 min denaturation at 95°C, 
followed by 45 cycles of amplification with 95°C denaturation for 15s, and 
annealing/extension at 60°C for 60s. Amplification data measured as an 
increase in reporter fluorescence were collected in real time, and Roche, Light 
Cycler 96 software was utilized for data analysis. 
The linear standard curves for JCPyV and BKPyV were obtained with a 
serial dilution of plasmids. For JCPyV amounts ranged from 1.2*10^2ng/μl to 
1.2*10^-2 ng/μl and for BKPyV from 9.5*10^0 to 9.5*10^-3 ng/μl. The 
standards for SV40 detection were constructed with a serial dilution of COS1 
cell line DNA containing one copy of SV40/cell. The number ranged from 
5.0*10^4 to 5.0*10^0cells/μl. The standards for the reference gene RNase P 
were acquired with a serial dilution of human placenta DNA extractions 
(Sigma-Aldrich, Darmstadt, Germany) ranging from 5.09*10^2 to 5.09*10^-
2. Cq values of less than 37 were considered to be a positive result, and the 
copy numbers were calculated as copies in 1 μg of human DNA. 
 
Table 4. Primers and probes for JCPyV, BKPyV, and SV40. 
Name Sequence detection 
JCPyV primer forward TTC TTC ATG GCA AAA CAG GTC TT 
JCPyV primer reverse GAA TGG GAA TCC TGG TGG AA 
BKPyV primer forward CTT TCT TTT TTT TTT GGG TGG TGT T 
BKPyV primer reverse TTG CCA GTG ATG AAG AAG CAA 
SV40 primer forward GAT GGC ATT TCT TCT GAG CAA A 
 
37 
SV40 primer reverse GAT GGC ATT TCT TCT GAG CAA A 
JCPyV T-ag probe 6 FAM CCA CTT CTC ATT AAA TG 
BKPyV T-ag probe 6 FAM AGT GTT GAG AAT CTG C 
SV40 T-ag probe 5′-FAM CAG GTT TTC CTC ATTAAA 
Abbreviations: JCPyV: JC Polyomavirus. BKPyV: BK Polyomavirus. SV40: 
Simian vacuolating virus 40. T-ag: T antigen. FAM: 6-carboxyfluorescein. A: 
Adenine. C: Cytosine. G: Guanine. T: Thymine. 
4.2.3 IMMUNOHISTOCHEMISTRY FOR JCPYV-POSITIVE 
TUMOR SAMPLES 
Only, JCPyV-positive tumor samples were further analyzed with 
immunohistochemistry for the T-ag, as all the samples remained BKPyV and 
SV40 DNA negative. Sections (thickness 4 μm) of formalin-fixed and paraffin-
embedded blocks were deparaffinized in xylene and rehydrated in a series of 
ethanol solutions. Thereafter, endogenous peroxidase activity was blocked by 
incubation of the slides with 3% hydrogen peroxide for 15 min. Epitope 
retrieval was performed using 1 mM citrate buffer, pH 6.0, and microwaved 
twice for 5 min. 
The primary antibody was a mouse monoclonal anti-simian virus T-ag 
(1:75) (Anti-SV40 Antibody, clone Pab101, LifeSpan BioSciences Inc., Seattle, 
WA, USA) which cross-reacts with JCPyV T-ag. The tissue was incubated with 
the primary antibody overnight and detected with Dako REAL Detection 
System (Peroxidase/DAB+, Rabbit/Mouse, Dako, Glostrup, Denmark), 
followed by counterstaining with hematoxylin. 
4.2.4 HPV DETECTION 
 
Extracted DNA was amplified with primer sets 1 and 2 from the Multiplex 
HPV Genotyping Kit® (DiaMex GmbH, Heidelberg, Germany). Primer set 1 
contained all HPV primers: nine biotinylated forward and three reverse 
primers for amplifying the HPV types under investigation. Primer set 2 (DNA 
quality control primers) contained primers for the amplification of a ß-globin 
gene fragment to verify the quantity and quality of human genomic sample 
DNA. A negative control contained no genomic DNA in order to confirm the 
absence of a contamination in the amplification reactions. Multiplex HPV 
Genotyping Kit® detected 24 low-risk (LR) and high-risk (HR) HPV 
genotypes as follows: LR-HPV6, -11, -42, -43, -44, and -70 and HR-HPV16, -
18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66, -68, -73, and -
82. To analyze the labeled hybrids a Luminex LX-100 analyzer was used (Bio-
Plex 200 System, Bio-Rad Laboratories, Hercules, CA, USA). 
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4.3 STUDY III 
For the immunohistochemical study, tumor tissue samples were available 
from 52 patients. The samples consisted of 44 primary tumors and eight 
recurrent tumors. The immunoexpression profile of MMP-7, -8, -9, -15, and -
25 was evaluated and immunoexpression of MMP-7, -9, -15, and -25 was 
associated with the clinicopathological factors and outcome. 
4.3.1 METHODOLOGY FOR MMPS, EMA, AND CEA 
 
Sections that were 4 μm thick cut from formalin-fixed and paraffin-
embedded blocks were deparaffinized in xylene and rehydrated in graded 
ethanol and distilled water. Tissue slides were heated in a PreTreatment 
module (Agilent Dako, Santa Clara, CA, USA) in Tris-EDTA buffer, pH 9.0 
(MMP-7, MMP-8, MMP-9) or in Tris−HCl buffer, pH 8.5 (MMP-15 and MMP-
25) for 20 min at 98◦C. Endogenous peroxidase activity was blocked by 
incubation of the slides with 0.3 % Dako REAL Peroxidase-Blocking Solution 
for 5 min and the primary antibody was diluted in Dako REAL Antibody 
Diluent. The primary antibodies were as follows: mouse monoclonal MMP-7 
antibody (1:1000) (EMD Millipore Corporation, Temecula, CA, USA), rabbit 
polyclonal MMP-8 antibody (1:400) 165, rabbit polyclonal MMP-9 antibody 
(1:2000) (Calbiochem, Merck KGaA, Darsmstadt, Germany), mouse 
monoclonal MMP-15 antibody (1:250) (EMD Millipore Corporation, 
Temecula, CA, USA), and rabbit polyclonal MMP-25 antibody (1:300) 
(Abbexa, Cambridge, UK). Incubation of tissues with primary antibodies was 
for 1 h, albeit overnight for MMP-8, followed by detection with Dako REAL 
Detection System (Peroxidase/DAB+, Rab- bit/Mouse, Dako, Glostrup, 
Denmark). Slides were visualized by Dako REAL DAB + Chromogen or HRP 
Magenta Chromogen for 10 min and finally counterstained with hematoxylin 
(Mayer’s Hematoxylin Dako, Glostrup, Denmark). Positive controls were oral 
mucosa and pancreas tissue for MMP-7, skin tissue for MMP-8, stomach and 
oral mucosa tissue for MMP-9, placenta and mammary gland tissue for MMP-
15, and colon tissue for MMP-25. 
Immunohistochemistry for EMA and CEA was performed in a routine 
laboratory with a Ventana Benchmark Ultra instrument (Roche, Tucson, AZ, 
USA). The slides were heated in a Ventana Cell Conditioning Solution (CC1) 
for 64 min for EMA and for 92 min for CEA. The primary antibody for EMA 
was clone E29, 790–4463 (ready-to-use), Ventana and for CEA clone II-7, 
M7072, (1:25), Dako. Incubation times were 40 and 60 min, respectively, 
followed by detection with a Ventana Ultraview DA, and finally 





Blinded to the clinical data, two independent researchers (H.H. and J.H.) 
scored the slides. The proportion of positively stained cells was estimated and 
immunoscores were grouped as follows: 0 for negative or very mild (0−10%), 
1 for mild (11–40%), 2 for moderate (41–70%), and 3 for strong (71–100%) 
positivity. This scoring method was modified from the previous publication of 
the Helsinki Head and Neck Research Group 123. The location of 
immunoexpression at the cellular level (cytoplasm, nucleus, cell membrane, 
cell type) was analyzed. The immunoexpression of MMP-9 in tumor-
surrounding inflammatory cells (PMN cells, lymphocytes, and plasma cells) 
and in luminal material of pseudocysts of ACC was additionally recorded. To 
validate the immunoexpression in normal tissue, normal salivary gland tissue 
present in the tumor slides was scored. EMA and CEA immunostainings were 
performed to ascertain the localization of MMP-9 immunopositivity in ACC 
tissues, particularly in relation to pseudocysts and true glands. EMA and CEA 
do not stain pseudocysts, although they are often positive in the true glands of 
ACC 166. 
 
4.4 STUDY IV 
Tumor tissue samples for AZIN1 immunohistochemical staining were 
available from 42 patients and comprised 35 primary and 7 recurrent tumors. 
For AZIN2, immunohistochemistry tumor samples were available from 45 
patients cand comprised 37 primary and 8 recurrent tumors. 
Immunoexpression profile of AZIN1 and -2 was evaluated and compared with 
the clinicopathological factors and outcome. 
4.4.1 METHODOLOGY FOR AZIN1 AND AZIN2 
 
Four μm thick sections cut from formalin-fixed and paraffin-embedded 
blocks were deparaffinized in xylene and rehydrated in graded ethanol and 
distilled water. Tissue slides were heated in a PreTreatment module (Agilent 
Dako, Santa Clara, CA, USA) in antibody-specific buffer, pH 9 for 20 min at 
98◦C for antigen retrieval. Endogenous peroxidase activity was blocked by 
incubation of the slides with EnVision Flex peroxidase-blocking reagent for 
15 min and the primary antibody was diluted in Dako REAL Antibody 
Diluent. The primary antibodies were as follows: rabbit polyclonal AZIN1 
antibody (1:500) (Biorbyt Ltd, Cambridge, UK) and K3 antibody (1:600) 162. 
The incubation times were overnight at +4°C and one hour at room 
temperature, respectively. This was followed by detection with the Dako 
REAL Detection System (Peroxidase/DAB+, Rabbit/Mouse, Dako, Glostrup, 
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Denmark), visualization with Dako REAL DAB+ Chromogen for 10 min, and 
counterstaining with hematoxylin (Mayer´s Hematoxylin Dako, Glostrup, 
Denmark). A positive control for AZIN1 was skin tissue and for AZIN2 gastric 
tissue. A slide without primary antibody was used as the negative control. 
4.4.2 IMMUNOSCORING 
 
Two independent researchers (H.H. and L.C.A.) performed scoring without 
knowledge of the clinical data. The location of immunoexpression on the 
different growth patterns (tubular, cribriform, and solid) was first analyzed. 
The proportion of positively stained tumor cells was estimated and 
immunoscores were grouped as follows: 0 for 0–10% (negative or very mild), 
1 for 11–40% (mild), 2 for 41–70% (moderate), and 3 for 71–100% (strong). 
The scoring and grouping methods were modified from the previous 
publication of the Helsinki Head and Neck Research Group 123. Normal 
salivary gland and apocrine gland tissue found on tumor slides was 
additionally immunoscored to validate immunoexpression in normal tissues. 
 
4.5 STATISTICAL METHODS 
IBM SPSS Statistics for Windows software was used for statistical analysis 
in Studies I, III, and IV (IBM Corp., Armonk, NY, USA, version 23.0 in Study 
I, version 25.0 in Studies III and IV). The Kaplan-Meier method was used for 
calculations of survival rates, and survival functions were compared with the 
log-rank test. 
In Study I, Cox regression analysis was utilized in univariate associations 
of risk factors with OS, DSS, and DFS. The risk factors that were associated 
with OS, DSS, and DFS (P< .05 in univariate analysis) were used in 
multivariate Cox regression model. The stage was not included in the same 
multivariate model with T or N classes due to avoiding the multicollinearity 
problems. Results were reported by using hazard ratios with 95% confidence 
intervals. 
In Studies III and IV, the Chi-squared test and Fisher´s exact test were used 
to evaluate the associations of MMP-7, -9, -15, and -25 and AZIN1 and -2 with 
clinicopathological factors. For statistical analysis, immunoscored tumor 
samples were grouped into different categories. In Study III, the categories 
were 0 (negative or very mild), 1 (mild), 2 (moderate), and 3 (strong), and in 
Study IV they were 0 (negative or very mild), 1 (mild), and 2-3 (moderate to 





4.6 ETHICAL CONSIDERATIONS 
The study concept was approved by the Institutional Research Ethics Board 
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University Hospital – Head and Neck Surgery. These retrospective studies 
consisted of reviewing hospital charts and histological specimens and did not 
have an effect on treatment of the patients included in the series. Therefore, 











5.1 CHARACTERISTICS AND OUTCOME OF MISG 
ACC PATIENTS (STUDY I) 
5.1.1 PATIENT AND TUMOR CHARACTERISTICS 
 
The patient and tumor characteristics of 68 MiSG ACC patients are described 
in Table 5 based on the location of the primary tumor. The whole cohort 
consisted of 39 women (57%) and 29 men (43%); thus, a female/male ratio of 
1.34. The median age was 58 years, ranging from 24 to 88 years. The majority 
of ACCs occurred in the oral cavity (41/68, 60%). Figure 7 shows the 
distribution of oral cavity ACCs. The most common location in the oral cavity 
was the palate (hard palate and the junction of the hard and soft palates) 
accounting for 49% of the intraoral ACCs occurred. Altogether 25% of tumors 
of the palate were stage I, 20% of stage II, 10% stage III, and 45% of stage IV 
tumors. 
 
Table 5. Patient and tumor characteristics of 68 minor salivary gland ACC 
patients treated at Helsinki University Hospital between 1974 and 2012. Six 
tracheal tumors are excluded from the TNM and stage classification. 
Location Oral 
cavity 
Oropharynx Nasopharynx Paranasal 
cavities 
Larynx Trachea Esophagus Ear 
N (total 68) 41 3 5 6 2 6 1 4 
Age         
≤65 years 24 2 5 5 1 5 1 3 
>65 years 17 1 - 1 1 1 - 1 
Sex, 
women/men 
19/22 3/0 4/1 2/4 2/0 6/0 0/1 3/1 
T class         
T1 12 3 - - 1  - 2 
T2 12 - - - -  - - 
T3 2 - 2 - -  1 1 
T4 12 - 2 6 1  - 1 
N/A 3 - 1 - -  - - 
N class         
N0 35 3 4 6 2  - 4 
N1 1 - - - -  - - 
N2 2 - - - -  1 - 
N/A 3 - 1 - -  - - 
M class         
M0 36 3 4 6 2  1 4 
M1 2 - - - -  - - 
N/A 3 - 1 - -  - - 
Stage         
I 10 3 - - 1  - 2 
II 12 - - - -  - - 
III 3 - 2 - -  1 1 
IV 13 - 2 6 1  - 1 
N/A 3 - 1 - -  - - 
Size, (mm) 10-100 13-18 10-46 22-60 13-22 3-23 19 8-45 
N/A 14 - 3 4 - 2 - - 
Resection 
margins 
        
Negative 18 1 1 - 1 1 - 1 
Positive 13 1 2 3 - 2 1 3 
43
N/A 10 1 2 3 1 3 - -
Abbreviations: T: Tumor. N: Node. M: Metastasis. N/A: Not available.
Figure 7. Distribution of 41 minor salivary gland adenoid cystic 
carcinomas of the oral cavity. A: Hard palate (n=15). B: Floor of mouth (n=6). 
C: Junction of hard and soft palate (n=5). D: Mobile tongue (n=5). E: Buccal 
mucosa (n=3). F: Gum (n=3). G: Upper lip (n=3). H: Mucous membrane of the 
oral cavity, not otherwise specified (n=1). Courtesy of Terhi Liuhto.
The primary symptoms were a lump (28%) and pain (18%). The duration 
of symptoms at the time of diagnosis had lasted from 1 to 240 months, with a 
median of 6 months. Three patients (4%) had a second primary malignancy at
the time of diagnosis. The malignancies were prostate carcinoma, 
chromophobe renal cell carcinoma, and thyroid papillary microcarcinoma.
Prior to treatment, the most commonly used imaging methods were head 
and neck CT (58%) and MRI (46%). Other preoperative examinations were 
chest CT scan (31%), ultrasound (16%), fine needle aspiration (12%), and 
positron emission tomography CT (6%).
The median tumor size was 21 mm (range, 3-100 mm). The size was not 
available for 23 tumors (34%) in the clinical data or by histological re-
evaluation. In the whole cohort, the most common growth pattern was 
cribriform (34%), followed by tubular (22%), combination of cribriform and 
tubular (19%), solid (9%), combination of cribriform and solid (7%), and 
combination of tubular and solid (2%). Growth pattern was not available in 
 
44 
five cases (7%). A combination growth pattern was considered unless a tumor 
sample comprised 80% of one growth pattern. Perineural or intraneural 
invasion, or both, was present in 39 tumors (57%). Information on neural 
invasion was not available for eight tumors (12%). 
5.1.2 TREATMENT 
 
The main treatment strategy was curative intent for 94% (64/68) of 
patients, 55% (35/64) of whom were treated with surgery as the sole treatment 
modality. Definite RT was given to one patient. Postoperative RT was given to 
38% (24/64) of patients, and the median dose was 60 Gy (range, 32-70 Gy). 
Of patients, 8% (5/64) had chemotherapy during their oncological treatment. 
Twenty-seven percent (17/64) of patients had neck dissection. Neck 
dissection was elective for 14 patients. Four patients had neck metastasis at 
the diagnosis. Three of these patients were treated with therapeutic neck 
dissection. Three patients with neck metastasis died due to ACC (range, 4-37 
months), and one patient was alive at the end of the follow-up (39 months). 
The treatment of ACC according to a tumor stage was relatively similar 
between different sites. Of patients with stage I and II tumors, 82% were 
treated with surgery alone. Only 22% of patients with advanced stage tumors 
(III-IV) were treated with surgery alone. Fifty-nine percent of patients with 
stage III and IV tumors received surgery combined with RT. Only 14% of 
patients treated with surgery and RT had stage I and II tumors. Patients who 
were offered oncological treatment had advanced ACCs in paranasal cavities 
and the nasopharynx, although one patient had stage I laryngeal ACC. 
One patient treated with curative intent was lost to follow-up. 
Altogether four patients (6%) received palliative treatment. Three of them 
had palliative surgery. One patient whose ACC was diagnosed in the 1970s did 
not receive any treatment. 
 
5.1.3 OUTCOME FOR PATIENTS TREATED WITH CURATIVE 
INTENT 
 
The 5-year OS and DSS rates were 70% and 79%, respectively. The 10-year 
OS and DSS rates were 42% and 52%, respectively. 
Women and patients aged under 65 years had better OS (P= .018 and .005, 
respectively). T classes 2-4, stages II-IV, and N+ neck were associated with 
decreased OS (P= .005, .019, and .003, respectively) and DSS (P< .001, .001, 
and .001, respectively). In addition, T classes 2-4 and stages II-IV were 
associated with poorer DFS (P= .001 and .002, respectively). Comparison of 
stage I and stages II-IV tumors showed that patients with stage I tumor 
survived significantly better and none died due to ACC (Figure 8). Especially, 
treatment between low-grade (stages I and II) ACC patients did not differ 
considerably. In addition, neural invasion associated with poorer DFS (P= 
.016), but positive neural invasion was not an independent prognostic variable 
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in multivariate Cox regression analysis. Neural invasion was not associated 




Figure 8. Kaplan-Meier plot showing a significant difference in the 
disease-specific survival of minor salivary gland adenoid cystic carcinoma 
patients with stage I compared with stage II-IV tumors. 
5.1.4 RECURRENT TUMORS OF PATIENTS TREATED WITH 
CURATIVE INTENT 
 
Overall, 53% (34/64) of patients treated with curative intent suffered from 
metastatic disease. Table 6 shows the distribution of recurrent tumors 
according to the primary tumor site for patients treated with curative intent. 
The majority (71%, 24/34) of recurrent tumors appeared within five years and 
29% (10/34) later. The patients having recurrent ACC within five years had 
significantly poorer OS (P< .001) and DSS (P< .001) than patients with no 
metastasis. However, late metastasis compared with no metastasis had no 
effect on OS or DSS (P= .216 and .054, respectively). Local and regional 
recurrent tumors associated with decreased DSS (P= .042 and .020, 
respectively). Distant metastasis significantly associated with both poorer OS 
and DSS (P= .009 and .001, respectively). Most distant metastasis appeared 
within 10 years. Two of the distant metastases occurred more than 10 years 
later, one after 11 years and the other after 13 years. 
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Table 6. Characterization of the outcome of 64 patients with minor 
salivary gland adenoid cystic carcinoma treated with curative intent. One 
patient could have several recurrent tumors. 
Tumor site Oral 
cavity 
Oropharynx Nasopharynx Paranasal 
cavities 





20/39 1/3 4/5 4/5 1/2 1/5 1/1 2/4 
Primary 
recurrence 
7 0 2 4 0 1 0 2 
Regional 4 0 0 0 0 1 0 0 
Distant 14 1 4 1 1 1 1 0 
Status         
NED 15 2 1 - 1 3 - 2 
AWD 4 1 - - - - - 1 
DOD 13 - 3 5 1 1 1 - 
DOC 7 - - - - 1 - 1 
N/A - - 1 - - - - - 
Abbreviations: NED: No evidence of disease. AWD: Alive with disease. 
DOD: Dead of disease. DOC: Dead of other cause. N/A: not available. 
 
 
Stage I ACC patients 
Three of 16 stage I patients treated with curative intent suffered from 
recurrent tumors: two local tumors (ACC in external ear canal) and one distant 
tumor (ACC in oropharynx). During the primary treatment 14 patients had 
surgery alone, one patient had surgery combined with RT (ACC in 
oropharynx), and one patient had chemoradiotherapy (ACC in larynx). 
Neural invasion was detected in 30% of the tumors. Inadequate surgical 
margins, i.e. tumor-positive surgical margins were detected in five tumors 
(two in ear, two in oral cavity, and one in oropharynx). Seven tumors had 
adequate surgical margins, i.e. tumor-negative margins (six in oral cavity and 
one in oropharynx), and for four patients information was not available (two 
in oral cavity, one in larynx, and one in oropharynx). Positive surgical margins 
were detected in both patients with stage I ACC in the ear canal. They were not 
treated with postoperative RT. Unfortunately, these patients later suffered 
from local recurrent tumors. Despite additional RT to the patient with 
oropharyngeal ACC, a distant metastasis occurred in the lungs. 
Altogether, despite a few recurrent tumors, patients with stage I ACC did 
not die due to ACC (range, 36-204 months). Four patients died due to causes 
other than ACC. Ten patients were alive with no evidence of ACC and two with 
disease at the end of the follow-up. 
 
Stage II ACC patients 
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Eight of 12 patients with stage II ACC in the oral cavity suffered from 
recurrent tumors. Nine patients were treated with surgery alone and three 
with surgery combined with postoperative RT. 
Neural invasion was detected in 67% of tumors. Surgical margin status was 
as follows: four tumor-positive and five tumor-negative surgical margins, and 
for three patients this information was not available. 
During the follow up, five patients had died due to ACC (range 28-78 
months) and one died due to another cause. Four patients were alive without 
recurrent tumors and two patients were alive with recurrent tumors. 
 
Stage III ACC patients 
Four of seven stage III patients had recurrent tumors. Surgery was offered 
to two patients with ACCs in the esophagus and oral cavity. Surgery combined 
with RT was offered to four patients with ACCs in the oral cavity (two), 
nasopharynx, and ear. One patient with nasopharyngeal ACC received only 
RT. 
Neural invasion was detected in 57% of tumors. Surgical margin status was 
the following: three positive (ACCs in oral cavity, nasopharynx, and 
esophagus) and two negative surgical margins (ACCs in oral cavity and ear), 
and for two patients this information was not available (ACCs in oral cavity 
and nasopharynx). 
All patients with recurrent ACC died due to the disease (range, 4-58 
months), and the rest were alive with no evidence of ACC. 
 
Stage IV ACC patients 
Fourteen of 20 patients with stage IV ACC had recurrent tumors. Surgery 
alone was offered to four patients, surgery combined with RT to 12 patients, 
solely RT to one patient, and chemoradiotherapy to three patients. 
Neural invasion was detected in 60% of tumors. Surgical margin status was 
the following: 10 positive (six in oral cavity, three in paranasal sinuses, and 
one in ear) and six negative surgical margins (four in oral cavity, one in larynx, 
and one in oropharynx), and for four patients this information was not 
available (two in paranasal sinuses, one in oral cavity, and one in 
nasopharynx). 
Twelve patients died due to ACC (range, 13-143 months) and one due to 
another cause. Four patients were alive with no evidence of ACC and two 
patients with the disease. One patient was lost to follow-up. 
 
5.2 JCPYV, BKPYV, SV40, AND HPVS IN MISG ACC 
(STUDY II) 
 
The presence of JCPyV, BKPyV, SV40, and 24 mucosal alpha HPV DNA 
genotypes in ACC was assessed. Seven of the 68 samples (10%) contained 
JCPyV DNA positivity. The low viral load of JCPyV varied from 1 to 226 
copies/μg DNA. Three samples showed slight nuclear immunopositivity for 
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large T-ag. Table 7 shows characteristics of patients with JCPyV DNA-positive 
tumors, and Figure 9 presents the locations of the tumors. Trachea, paranasal 
cavity, and oral cavity were the primary locations of JCPyV DNA-positive 
tumors. Furthermore, one JCPyV positive sample was derived from a lung 
metastasis of a tracheal tumor and one from the local recurrence of an oral 
cavity tumor.
None of the samples contained DNA of BKPyV, SV40, or any of the tested 
24 HPV genotypes. Normal salivary gland control tissue samples were 
negative for JCPyV, BKPyV, and SV40.
Table 7. Characteristics of patients with JC polyomavirus DNA-positive 
adenoid cystic carcinomas.
Patient Tumor location Sex Age TNM Treatment Recurrence Status
#1 Trachea Woman 43 Surgery Distant DOC
#2 Trachea Woman 54 Surgery NED
#3 Trachea (lung 
metastasis)
Woman 47 Surgery Distant, local, 
locoregional
DOD
#4 Paranasal sinuses Man 60 T4BN0M0 Oncological Local DOC
#5 Oral cavity, gum Woman 80 T1N0M0 Surgery DOC
#6 Oral cavity, hard palate Man 59 T4BN0M0 Surgery and 
oncological
DOC
#7 Oral cavity, floor of 
mouth (local recurrence)
Woman 72 T4AN0M1 Surgery Local DOD
Abbreviations: T: Tumor. N: Node. M: Metastasis. DOC: Dead of other 
cause. NED: No evidence of disease. DOD: Dead of disease.
Figure 9. Locations of JCPyV DNA-positive adenoid cystic carcinomas.
Courtesy of Ruusu Hulmi.
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5.3 MMPS IN MISG ACC (STUDY III) 
MMP-7, -8, -9, -15 and -25 immunoexpression in MiSG ACC was analyzed 
and examined in association with clinicopathological parameters and survival. 
Table 8 shows the distribution of the MMP immunoscoring. ACC did not 
immunoexpress MMP-8. 
 
Table 8. Distribution of matrix metalloproteinase -7, -9, -15, and -25 
immunoscoring in 52 minor salivary gland adenoid cystic carcinomas. 
Immunoscore 0 1 2 3 N/A Total Luminal Inf. cells Normal SG 
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- Pos. Neg. 
Abbreviations: 0: Negative or very mild immunoexpression. 1: Mild 
immunoexpression. 2: Moderate immunoexpression. 3: Strong 
immunoexpression. N/A: Not available. Luminal: Immunoexpression in 
luminal material of many pseudocysts and a few true glands of ACC. Inf. cells: 
Immunoexpression in inflammatory cells. Normal SG: Immunoexpression in 
normal salivary gland. MMP: Matrix metalloproteinase. 
5.3.1 ASSOCIATION BETWEEN MMPS AND 
CLINICOPATHOLOGICAL FACTORS 
 
In Chi-squared test and Fisher´s exact test, high tumoral MMP-9 
immunoexpression associated with advanced stage (P= .026) and with 
regional metastases (P= .035). MMP-9 positivity in luminal material of 
pseudocysts of ACC associated with better OS and DSS (P< .001) and with 
fewer local recurrent tumors (P= .031). MMP-9 positivity in inflammatory 
cells associated with immunopositivity in pseudocysts of ACC (P= .012) and 
with fewer local recurrent ACCs (P= .037). Abundant MMP-25 
immunoexpression associated with better OS (P= .043). 
In Kaplan-Meier survival analysis, abundant tumoral MMP-7 
immunopositivity associated with better OS and DSS (P= .043 and .025, 
respectively). Abundant tumoral MMP-15 immunoexpression associated with 
poorer DSS (P= .041). High MMP-9 immunoexpression in pseudocysts of ACC 
associated with OS and DSS (P= .020 and .012, respectively). 
The following clinicopathological factors were not significantly associated 
with any of the MMPs: gender, age, T, N, and M classification, neural invasion, 
and distant metastasis. 
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5.3.2 MMPS IN JCPYV DNA-POSITIVE SAMPLES 
 
JCPyV DNA-positive and -negative samples were compared with 
immunoexpression of MMP-7, -9, -15, and -25 by using Fisher´s exact test. No 
statistically significant associations emerged with immunoexpression of 
MMP-7 and -9. Low MMP-15 and -25 immunoexpression associated with 
JCPyV DNA-positive samples (P= .004 and .041, respectively). However, there 
were only seven JCPyV DNA-positive samples. 
 
5.4 AZINS IN MISG ACC (STUDY IV) 
 
AZIN1 and -2 immunoexpression in MiSG ACC was analyzed and examined 
in association with clinicopathological parameters and survival. 
5.4.1 IMMUNOEXPRESSION OF AZINS 
 
Table 9 shows the distribution of AZIN1 and -2 immunoscoring. 
Immunohistochemistry of AZIN1 showed the strongest positivity in the 
cribriform growth pattern of ACC, followed by the tubular and solid patterns. 
Generally, AZIN1 immunoexpression was milder than AZIN2 
immunoexpression. In normal structures, AZIN1 immunoexpression was 
present in apocrine glands, sweat glands, muscle cells, hair follicles, and 
germinal centers of lymphoid tissue. 
AZIN2 immunohistochemical staining was strongest in the tubular growth 
pattern of ACC, followed by the cribriform and solid patterns. In normal 
structures, AZIN2 immunoexpression was present in mast cells, type 2 
pneumocytes, neural structures, sweat glands, and minor salivary glands. 
 
Table 9. Distribution of antizyme inhibitor 1 and 2 immunoscoring in 
minor salivary gland adenoid cystic carcinomas. 
Immunoscore 0 1 2 3 
AZIN1 (total 42) 13 (31%) 18 (43%) 9 (21%) 2 (5%) 
AZIN2 (total 45) 2 (4%) 11 (25%) 24 (53%) 8 (18%) 
Abbreviations: 0: Negative or very mild immunoexpression. 1: Mild 
immunoexpression. 2: Moderate immunoexpression. 3: Strong 
immunoexpression. AZIN: Antizyme inhibitor. 





In Chi-squared test and Fisher´s exact test, abundant immunoexpression 
of AZIN2 was associated with longer OS and DSS (P= .006 and P= .004, 
respectively). 
In Kaplan-Meier survival analysis, abundant immunoexpression of AZIN2 
associated with better DSS and DFS (P= .049). 
The following clinicopathological factors were not associated with AZIN2: 
gender, age, T, N, and M classification, stage, neural invasion, and recurrent 







Among rare SGCs, ACC is the second most common histologic subtype. The 
long-term prognosis of ACC is poor. Thus, diagnosing MiSG ACC at an early 
stage, preferably at stage I, markedly benefits patient survival. Treatment of 
these tumors has been similar over the years, highlighting the importance of 
surgery and postoperative radiotherapy. However, studies on molecular 
pathogenesis and target-specific therapies are active. 
In this thesis, the behavioral pattern of MiSG ACC was evaluated in a 
Finnish population (Study I). The presence of three polyomaviruses and 24 
HPVs in MiSG ACC were assessed to study viral participation in the 
pathogenesis of ACC (Study II). Studies on MMPs in SGCs are sparse and this 
study aimed to investigate their prognostic role in the current cohort of MiSG 
ACCs (Study III). AZIN1 and -2 have not been previously evaluated in SGC or 
salivary gland tissue. Thus, an attempt was made to clarify the prognostic role 
of AZINs in ACC (Study IV). 
 
6.1 PROGNOSTIC FACTORS FOR MISG ACC 
PATIENTS (STUDY I) 
Based on Study I, the prognostic factors for MiSG ACC are gender, age, T 
and N classes, stage, neural invasion, and recurrent tumors. 
Female gender predicting better OS was consistent with earlier studies on 
ACC 77, 167. Aging has been previously related to poorer survival in ACC, 
similarly to other SGCs 29, 76, 77. In the current study, age >65 years predicted 
poorer OS. Such predictive factors as gender and aging are not obviously only 
related to ACC because in general women have higher life expectancy and 
younger patients cope better with the side effects of cancer therapy. 
Most of the MiSG ACCs occurred in the oral cavity (60%). The most 
common intraoral site was the palate (49%), as described earlier 45, 68-70, 142. In 
the current study, 75% of palatal tumors were stages II-IV. The series of 
intraoral ACCs by Shum et al. demonstrated earlier that high numbers of 
palatal ACCs are diagnosed as advanced tumors 46. The present and earlier 
results highlight the difficult and often late diagnosis of palatal ACCs. 
Importantly, a lump in the palate must always be further investigated to 
exclude the possibility of a salivary gland tumor. 
In the current study, T classes 2-4 and stages II-IV associated with 
decreased OS, DSS, and DFS. Notably, patients with stage I ACC clearly had a 
better prognosis than patients with stage II ACC. Recurrent tumors affected 
only three of the 16 stage I patients, whereas eight of the 12 stage II patients 
had recurrent ACCs. In the case of positive surgical margins with stage I ACC, 
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it seemed that the postoperative RT was not necessary to avoid recurrent 
tumors if re-surgery was possible. Based on this patient cohort, stage II ACC 
appears to be a more unpredictable disease than stage I ACC. However, 
treatment between stage I and II ACC patients was quite similar. Therefore, 
adding treatment efforts to stage II patients and following them more closely 
could be beneficial for these patients. Earlier studies on MiSG ACC have 
concluded that early-stage ACC is a predictor of a better prognosis, although 
these studies have not emphasized a better prognosis for T1 and stage I tumors 
than for T2 and stage II tumors 44, 45, 68, 70. 
With the complex anatomy of the ear, it seemed that postoperative RT 
would be feasible with positive surgical margins even with stage I tumors. In 
this study, two patients with stage I ACC in the external ear canal were not 
treated with postoperative RT, although the surgical margins were tumor-
positive, leading to local recurrent tumors. With ACC in the external ear canal, 
local recurrencies have been shown to be associated with distant metastasis, 
occurring in 30% of the cases 168. Zhang et al. concluded that postoperative RT 
was indicative for advanced ACC of the external ear canal 168. In the present 
study, two patients with advanced ACC occurring in the external ear canal were 
treated with surgery and postoperative RT. Positive surgical margins were 
detected in one case. However, the treatment was successful and recurrent 
ACC was avoided. 
In the present study, N+ neck at presentation predicted poorer OS and 
DSS. This finding correlates with earlier studies 68, 70. In the present study, only 
four patients suffered from N+ neck and their advanced ACCs were located in 
the oral cavity and one in the esophagus. These patients were treated with neck 
dissection, but three of the four patients died due to ACC within three years. 
One patient was alive at the end of the follow up (39 months). Based on these 
findings, N+ neck is a predictor of a poor survival regardless of thorough 
treatment efforts. 
Neurotropism is related to ACC, and in the current study neural invasion 
predicted poorer DFS. Similarly, earlier studies have shown that perineural 
invasion predicts poorer treatment outcome 169-171. In this study, stages II-IV 
ACC presented more often with neural invasion than stage I ACC. ACC is a 
slow-growing SGC but with growing tumor size raises the possibility of 
detecting neural invasion. 
In the present study, comparison of survival of patients with metastatic 
disease in relation to primary tumor site was not possible. The number of cases 
in a few sites was limited, and statistical power was insufficient for all sites. 
According to an earlier study, patients with oral cavity tumors have been 
shown to have superior survival to patients with tumors arising in MaSG, nasal 
cavity, larynx, and bronchus 77. Moreover, poor survival has been shown with 
ACC occurring in sinonasal cavities 75, 76. A patient might notice a tumor in the 
oral cavity easier and seek medical help. In addition, tumor-free surgical 
margins seem to be more difficult to achieve in the upper airways than in the 
oral cavity. The present study includes ACC patients from five decades, 
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reflecting the different treatment modalities over time. Nowadays 
sophisticated surgical approaches could be successful in the treatment of these 
high-risk sites. 
The present study shows that regardless of the location, MiSG ACC 
metastasizes in 53% of cases. In the studies including both MiSG and MaSG 
ACCs, the proportion of metastasis has varied from 35% to 60% 8, 172. In the 
present study, metastasis appeared more commonly within five years. The 
patients with early metastasis had decreased OS and DSS. Primary 
recurrencies and regional and distant metastases all had a negative effect on 
survival. Stages II-IV ACC produce more metastasis than stage I ACC. 
Distant metastasis has been related to high-risk ACC locations such as the 
maxillary sinus and tongue 83 In this study, among curatively treated patients, 
distant metastasis appeared in 67% of patients who had metastasis. In the 
cohort of MaSG ACCs drawn from the same area and population as the present 
study, the rate of distant metastasis was 50% 173. Similarly, Matsuba et al. have 
shown that 50% of MiSG and MaSG ACCs develop distant metastasis 28. In this 
study, all distant metastasis appeared within 13 years. Close follow-up is 
feasible and the follow-up time should be at least 10 years. 
 
6.2 VIRAL LOAD IN MISG ACC (STUDY II) 
The presence of JCPyV, BKPyV, and SV40 and 24 alpha HPVs in ACC was 
studied and only JCPyV DNA (10%) was detected in the samples. These results 
indicate that the prevalence of JCPyV is infrequent in MiSG ACC. However, 
the viral presence could be one step towards malignancy. Given that, JCPyV 
could contribute to the pathogenesis of a small proportion of ACCs. 
The seroprevalences of BKPyV and JCPyV are common among the adult 
population, being 82-99% and 39-81%, respectively 89, but also among 
children 90. As the infection with these two viruses classified as grade 2B 
carcinogens is so common, it is tempting to speculate their possible role also 
in several carcinomas among SGCs. BKPyV is shed in saliva and viral 
replication is shown to occur in vitro in salivary gland cells 174. In the head and 
neck area, tonsil tissue has been proposed to serve as a reservoir for BKPyV 
and JCPyV, which have been detected to some extent in the oropharynx 99, 100. 
JCPyV, BKPyV, and SV40 have also been detected in salivary gland tumors 108, 
112 but none of these tumors were ACCs. However, the results are still 
contradictory. Ramqvist et al. did not detect any BKPyV or JCPyV in their 
series of different SGCs, but MCPyV was present in three SGCs, including one 
ACC 175. They studied 10 HPyV types from parotid gland SGCs, with SGC 
subtypes varying from one to 19 175. In the present study, the total number of 
ACCs was representative (n=68) with 10% of JCPyV positive tumors. 
Previously, inoculation of a mouse polyomavirus to MaSG of a mouse resulted 
in a benign tumor formation, resembling a pleomorphic adenoma 111. Sandros 
 
55 
et al. inoculated polyoma virus into newborn mice, which developed 
adenocarcinomas in less than three months. Typical for these tumors was viral 
integration and karyotypic instability 176. 
Despite the evidence from animal models of polyomavirus inoculation 
leading to tumor formation, the role for JCPyV in human cancers and tumor 
formation is unclear and remains a subject of debate 177. After primary 
infection, JCPyV latency is described in the kidney and urothelial tissue, and 
JCPyV DNA is detected in normal colonic mucosa 178. Furthermore, JCPyV has 
been detected in urothelial carcinoma 178, in brain tumors 179, in colorectal 
neoplasia of liver transplant patients 180, and in cancers of the gastrointestinal 
tract 181, while others report no correlation 177. 
The incidence of SGC is increasing 182-184, but the reason for this trend 
remains obscure. Possible explanations could be improvements in diagnosing 
different subtypes of SGC, and yet unknown risk factors and their role in 
activating or establishing the latency of oncoviruses. Approximately 8.3% of 
human cancers are caused by oncoviruses 92. Studies on viral etiology of 
salivary gland tumors are often focused on salivary gland tumors as such but 
not on a specific malignant tumor type. As known, the molecular landscape of 
SGC subtypes is different, indicating that their pathogenesis differs from each 
other. Clarifying the prevalence, viral physical state, and viral transcription 
pattern of all potential oncoviruses according to the SGC entity would cast 
more light on this complex issue. Pathogenesis of SGC could perhaps be 
different between MiSGs and MaSGs due to their different anatomical 
locations and their physical features (e.g. secretion). 
In general, the number of virus-related head and neck cancers has increased 
especially due to HPV infection. In the present study, HPV DNA was not 
detected in the ACC samples. Compared with previous studies on SGC, the 
current series with ACC as the only tumor entity is representative. There are 
only few studies on the role of HPVs in SGCs 30-32, 116, 185-189. Haeggblom et al. 
did not detect HPVs in salivary gland tumors including 13 ACCs 31, confirming 
the findings from Skálová et al. 30 and Bishop et al. 116. Qian et al. detected 
HPVs in 42% of ACCs 186. HPV DNA-positive tumors and negative resection 
margins predicted better recurrence-free survival. The association with HR-
HPVs was slightly stronger in MaSG ACCs (44%) than in MiSG ACCs (38%) 
186. To conclude, the studies on the association between HPV and SGC are 
scarce, and the results are conflicting 30-32, 116, 185-189. The present data do not 
support a specific role of HPV in the pathogenesis of ACC. 
 
6.3 MMPS IN MISG ACC (STUDY III) 
In this study, MMP-9 immunoexpression associated with poorer prognosis 
such as advanced stage and regional metastasis. Similar findings with adverse 
effects of MMP-9 immunoexpression have been shown previously. High 
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MMP-9 immunoexpression in ACC has been established to be related to 
poorer prognosis such as advanced stage, solid growth pattern, perineural 
invasion, recurrences, and shorter survival time 140. Souza Freitas et al. have 
shown abundant MMP-9 immunoexpression in ACC compared with a normal 
salivary gland 142. Interestingly, in this study, MMP-9 immunoexpression in 
the luminal material of pseudocysts of ACC and in inflammatory cells close to 
the tumor associated with better prognosis. MMP-9 immunoexpression in 
pseudocysts associated with better survival and fewer local recurrent tumors, 
while immunoexpression in inflammatory cells associated with fewer local 
recurrent tumors and positivity in pseudocysts. Possibly within these tumors, 
MMP-9 was not active when located in the luminal material of pseudocysts or 
in inflammatory cells. Pujada et al. have suggested that in colitis-associated 
colorectal cancer MMP-9 might act as a tumor suppressor 190, which is 
contrary to the current knowledge of the role of MMP-9 in tumor invasion and 
metastasis 130. 
In the present study, abundant MMP-7 immunoexpression associated with 
longer OS and DSS. This was consistent with the results of Luukkaa et al. of an 
association between MMP-7 immunoexpression and better prognosis of SGC 
122. 
This study was the first to demonstrate an MMP-15 and MMP-25 
immunoexpression pattern in SGC and in normal salivary gland tissue. 
Abundant MMP-15 immunoexpression associated with decreased survival 
time. Previously, abundant MMP-15 immunoexpression in laryngeal SCC has 
been related to metastatic behavior 148. In the present study, high 
immunoexpression of MMP-25 in ACC associated with better survival. 
Previous studies examining the relationship between MMP-25 and head neck 
cancer are limited 123. ACC cells did not immunoexpress MMP-8. 
Only a few studies have been examined the functions of MMPs in the 
carcinogenesis and microenvironment of SGC 122, 138-142, 191-193. Specific 
behavior of MMPs in SGCs among ACC is not fully understood, but MMPs 
could function especially during metastasis. MMPs can process ECM and non-
matrix bioactive molecules (cytokines, hormones, defensins, immune 
mediators, other proteases, adhesion molecules, growth factors, and cell 
surface receptors). Due to this ability, MMPs are important in a cancer cell. 
Metastasis is a multistep process that includes decreased cell adhesion, 
increased motility and invasion, proteolysis, and resistance to apoptosis. 
Especially, interactions between MMPs and claudins (cell membrane protein 
family) might play an important role in invasive behavior of cancer cells and 
metastasis. 194 
To study the relations between virus DNA-positive samples and 
immunoexpression of MMPs, this study associated MMP immunoexpression 
with JCPyV DNA-positive and -negative samples. With JCPyV DNA-positive 
samples, MMP-15 and MMP-25 immunoexpressions were significantly 
weaker. Previously, Liu et al. have been interested in the functions of MMPs in 
MCPyV infection. They studied whether MMP-mediated degrading of ECM 
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could stimulate MCPyV infection, leading to tumorigenesis of MCC 195. They 
showed that induction of MMP genes by the WNT/Beta-catenin signaling 
pathway and other growth factors stimulate MCPyV infection. The 
transcription of several MMP genes (MMP-1, MMP-3, MMP-7, MMP-9, MMP-
10, MMP-11, and MMP-13) was increased in dermal cells. However, no 
increase in mRNA levels of MMP-15 and MMP-25 genes was found. 195 In the 
current study, within JCPyV DNA-positive samples, MMP-15 and MMP-25 
immunoexpressions were weaker than in virus-negative samples. MMP-7 and 
MMP-9 immunoexpressions were not associated with the virus DNA-positive 
samples. Previously, an association has been shown between MMP-9 and 
JCPyV reactivation during the treatment of multiple sclerosis patients with 
humanized monoclonal antibody against the cell adhesion molecule α4-
integrin (natalizumab) 196. MMP-9 plasma level was shown to increase at the 
time of JCPyV reactivation 196. 
This study showed that ACC tissue immunoexpressed MMPs. MMPs are 
known to activate each other (e.g. MMP-7 activates MMP-8 and -9), and they 
stimulate cascades that may promote tissue modulation and metastatic 
potential of cancer cells. In the future, additional studies on the role of MMPs 
in SGC are warranted. 
 
6.4 AZINS IN MISG ACC (STUDY IV) 
In this study, high AZIN2 immunoexpression associated with longer OS 
and DSS. AZIN1 immunoexpression did not have any statistically significant 
associations with the studied clinicopathological factors and survival. 
Recently, AZIN2 has been related to poorer prognosis of colorectal 
adenocarcinoma 197, which was the reason for conducting this study on AZINs 
in salivary gland adenocarcinoma. However, specific molecular events have 
not yet been revealed behind AZIN2. Furthermore, recently, Shigeyasu et al. 
have shown that epigenetic modification (RNA editing) of AZIN1 in colorectal 
cancer seems to drive the metastatic process and could be used as a prognostic 
factor 198. 
In the current study, AZIN1 and AZIN2 were seen in tubular and cribriform 
growth patterns with secretory functions rather than in the solid pattern. This 
finding is similar to that of Kaprio et al. 197, who described abundant AZIN2 
immunoexpression in mucinous colorectal cancer tissue with secreting 
functions. Solid ACC is poorly differentiated, and it might have lost some of 
the normal cell functions, e.g. the vesicle transportation system. In tubular and 
cribriform patterns, ductal structures formed by luminal (epithelial) cells are 
numerous compared with the solid pattern, which is mainly composed of 
basal/myoepithelial cells with a few ductal structures. 
This study was the first to show AZIN1 and -2 in salivary gland carcinoma 
and in normal salivary gland tissue. MiSG structures representing normal 
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salivary gland tissue in the immediate vicinity of ACC lacked the 
immunoexpression of AZIN1. However, AZIN2 immunoexpression was 
present in ductal structures of MiSG. Previously, abundant AZIN2 expression 
has been shown in terminally differentiated cells, namely neurons, adipocytes, 
acinar cells of sweat glands, and megakaryocytes in bone marrow 199. 
Interestingly, AZIN2 has been shown to regulate vesicle transportation in a 
cell and mast cell degranulation process 200, 201. 
AZINs have an important role in cellular functions, contributing to 
polyamine synthesis. AZIN1 has been studied more than AZIN2. In 
pathological circumstances, AZIN1 has been related to formation of gastric, 
breast, hepatocellular and esophageal cancers 160. Specific molecular events of 
AZINs in normal and cancer cells warrant clarification. Both AZINs have been 
proposed for use as therapeutic agents against cancer 153, 198. 
 
6.5 LIMITATIONS AND STRENGTHS OF THE 
THESIS 
Study I included patients from one tertiary care academic center, and the 
number of patients was large compared with previous studies on MiSG ACC. 
The study material was partly old and collecting data on all cases was not 
possible. For example, details of vascular invasion and surgical margins were 
not always reported. Statistical analysis based on these parameters could not 
be conducted. In the cohort, MiSG ACCs from eight different subsites were 
studied. In a few locations, such as paranasal sinuses, the number of cases was 
limited in order to statistically evaluate separately anatomical subsites. Within 
the long period of the retrospective study, the diagnostic assessment and 
treatment modalities have evolved. One patient was lost to follow-up due to 
moving to another European country. However, the follow-up time for all the 
patients was at least three years. 
In Study II, viral load of MiSG ACC samples was studied. The total sample 
size of this one tumor entity was large relative to previous SGC studies on 
oncoviruses. qPCR method is reliable for detecting viral load in tissue samples. 
JCPyV DNA was detectable, but levels were quite low. Detection of JCPyV 
DNA by immunohistochemistry proved to be challenging due to small viral 
load. 
In Studies III and IV, immunoexpressions of biomarkers (MMP-7, -8, -9, -
15, and -25 and AZIN1 and -2) were related to clinicopathological parameters 
and survival. Unfortunately, tissue samples from all cases were not available, 
likely because some of the oldest tissue samples had already been exhausted. 
The small sample size in the studies of rare diseases, such as ACC, is a common 
limitation. Other limitation is that determining the proportion of positive 
staining is subjective. To avoid bias in evaluating the immunohistochemical 
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staining, two researchers performed the scoring separately, afterwards 







1. Stage II MiSG ACC patients suffered from more unpredictable 
and aggressive disease than stage I patients. Treatment strategy of stage II 
ACC patients should be customized, as these patients have advanced disease. 
Of palatal ACCs, 75% were stages II-IV, which demonstrates the difficulty of 
the early diagnosis. Clinicians should always consider a lump in the palate as 
a possible salivary gland tumor and further investigate the area. 
Older age, advanced T class and stage, N+ neck at diagnosis, and 
locoregional and distant metastases had negative associations with survival. 
Of the patients, 53% developed metastases during the follow-up. Distant 
metastases appeared within ten years, except for two patients with 
manifestation within 13 years. Thus, prolonged follow-up, (at least ten years), 
is recommended. 
 
2. JCPyV DNA was detected from MiSG ACC samples in the upper 
and lower airways. However, BKPyV, SV40, and HPVs were not found. JCPyV 
could be a part of tumorigenesis of ACC in a small proportion of ACC patients. 
While the presence of low copy numbers of JCPyV DNA in itself does not 
establish causation, one cannot exclude the viral role in early malignant 
transformation according to the hit and run model of carcinogenesis. 
 
3. MMP-7, -9, -15, -and 25 were immunoexpressed in MiSG ACC. 
Inflammatory cells immunoexpressed MMP-8, -9, and -25. High tumoral 
MMP-9 and MMP-15 immunoexpression associated with poorer prognosis. In 
contrast, high tumoral MMP-7 and MMP-25, and high MMP-9 in the luminal 
structures of pseudocysts of ACC and in inflammatory cells surrounding the 
tumor, associated with better prognosis. MMPs are known to function in 
different activating cascades and in immunomodulation. Thus MMP-7, -8, and 
-9 can take part in tissue modulation and in the metastatic process. MMP-15 
and -25 are related to prognosis. 
 
4. This study was the first to show AZIN1 and -2 immunoexpression 
patterns in ACC. Both AZINs were markedly present in well-differentiated 
growth patterns, namely tubular and cribriform patterns compared with the 
solid growth pattern. Abundant AZIN2 immunoexpression associated with 
longer OS and DSS. With the knowledge that AZIN2 contributes to vesicle 
transportation, it may be speculated that AZIN2 participates in vesicle 
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